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Dysferlinopathies are a heterogeneous group of congenital muscle disorders characterized by 
late-onset muscular dystrophy and increased muscle prowess before onset of symptoms. 
Mutations in the DYSF gene encoding the protein dysferlin have been identified as the 
common genetic cause of this rare disease spectrum. However, little is known about the 
pathomechanism leading to muscle degeneration and therefore, no curative treatment is 
available. Dysferlin is a tail-anchored multi-C2 domain protein belonging to the ferlin protein 
family. For a long time, it has mainly been implicated in membrane repair. In recent years, new 
evidence uncovered an additional and fundamental role for dysferlin: the formation of the T-
tubule system in skeletal muscle.  
The aim of this study was to further elucidate the cellular role in skeletal and heart muscle and 
the trafficking of dysferlin. This would help to reveal the molecular pathomechanism of 
dysferlin-deficient muscular dystrophy and give the possibility to identify new targets for the 
development of therapeutic approaches.  
The finding of an abnormal T-tubule system in developing dysferlinopathy patient myotubes 
suggests that dysferlin is essential during a very early stage of T-tubule biogenesis in skeletal 
muscle. Not only the T-tubule system in skeletal muscle, but also the cardiac tubular system of 
dysferlin-deficient mice is altered with loss and axialization of membrane tubules. This finding, 
together with the localization and increased expression of dysferlin at the developing T-tubule 
system in cardiomyocytes, support the role of dysferlin as a key player of cardiac T-tubule 
biogenesis. Furthermore, these findings may explain the pathology of dysferlin-deficiency in 
skeletal and heart muscle. The investigation of the cellular trafficking shows that mutated 
dysferlin is retained in the endoplasmic reticulum or Golgi network and provides evidence that 
functional dysferlin follows the secretory pathway to reach the plasma and T-tubule 
membrane. Treatment with the chemical chaperone 4-phenylbutyrate (PBA) increases the 
steady-state protein levels and partially rescues functional deficits of dysferlin mutants. Thus, 
PBA might be a potential therapeutic for the treatment of dysferlinopathy. Another 
therapeutic approach is the induction of translational readthrough by aminoglycosides in 
patients harboring nonsense DYSF mutations. The systematic analysis of readthrough 
induction for all recurrent DYSF nonsense mutations revealed a high variety of readthrough 
efficiency and might provide a suitable prediction for the treatability of dysferlinopathy 
patients. This gives the possibility to selectively treat patients with high therapeutic potential 
as aminoglycosides are associated with severe adverse effects.  
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1.1 Skeletal muscle anatomy and function 
The skeletal muscle fiber is a syncytium originating from fusion of myogenic precursor cells, 
myoblasts, into elongated multinucleated myotubes during myogenesis (Holtzer and Abbott, 
1958).  The highly organized complex of large tube-shaped cells is one of the prerequisites for 
optimal force development. Another requirement for precise muscle function is the temporal 
coupling of the motor neuron signal to the contraction of the myofiber. Muscle fibers possess 
an extensive membrane system, the transverse tubule system (T-tubule system) (Franzini-
armstrong and Porter, 1964), composed of tube-shaped plasma membrane (sarcolemma) 
invaginations with a diameter of approximately 20 – 40 nm which transversally penetrate the 
whole fiber (Franzini-Armstrong et al., 1975). The T-tubules congregate with the terminal 
cisternae of the longitudinally orientated sarcoplasmic reticulum (SR) to form anatomical and 
functional structures called triads. One triad is composed of one T-tubule enclosed by two SR 
cisternae (Figure 1). The T-tubule and SR membranes are located in very close proximity with a 
gap of 12 nm (Boncompagni et al., 2006). 
 
 
Figure 1 | Triad structure and T-tubule system in the skeletal muscle.  (A) Electron micrograph of a 
triad structure. A central T-tubule is enclosed on both sides by one terminal cisterna of the SR. Arrows 
indicate electron-dense structures between the T-tubule and SR membrane representing the DHPR-
RyR1 complex. (B) Schematic representation of a skeletal muscle basic unit and surrounding 
membranes. T-tubules (gray) are transverse invaginations continuous with the plasma membrane. The 
SR network (blue) expands longitudinally along the muscle fiber. Adapted from Marieb & Hoehn, 2007, 
© 2007 by Pearson Education, Inc.  
 
The action potential, which is generated through electrochemical signal transduction, is not 
restricted to the sarcolemma but propagates along the T-tubule system into the interior of the 





contraction coupling (EC coupling). In this process, depolarization of the T-tubule membrane 
leads to activation of the voltage-sensitive L-type Ca2+ channel (Dihydropyridine receptor, 
CaV1.1) which is directly coupled to the Ca
2+-releasing ryanodine receptor 1 (RyR1) of the SR 
membrane. Opening of RyR1 allows fast release of Ca2+ from the SR, the main Ca2+ store of the 
muscle fiber, and muscle contraction (Ashcroft, 1991; Bezanilla et al., 1972) (Figure 2). When 
the coupling of these two receptors is disturbed for instance by an abnormally configured 
structure of T-tubule and SR membranes the process of EC coupling and directly Ca2+ 
homeostasis are affected (Tjondrokoesoemo et al., 2011).  
 
 
Figure 2 | Excitation-contraction coupling in skeletal myofibers.  Scheme showing the connection 
between an electical action potential and the cytoplasmic Ca
2+
 increase at the triad, finally, leading to 
contraction of the skeletal myofiber. The neurotransmitter released by terminal synapses of 
motoneurons leads to depolarization of the myofiber sarcolemma. The action potential propagates 
along the membrane of the T-tubule system into the inner of the fiber and activates voltage-sentive 
Ca
2+
 channels of the skeletal muscle, CaV1.1. Conformational change of CaV1.1 leads via direct 
interaction with the Ca
2+
 release channel RyR1 to its opening and massive influx of Ca
2+
 from the SR into 
the cytoplasm. 
 
1.2 Cardiac T-tubule system 
Besides the skeletal, also the heart muscle is described as striated due to the highly organized 
arrangement of sarcomeres, the contractile units of muscle cells. Still, there are 
morphological, functional and molecular differences between skeletal myofibers and 





but are mainly mono- or binucleated (Bensley et al., 2016). Ventricular cardiomyocytes 
possess a tubular membrane system which was initially thought to have exclusively a 
transverse orientation to the long axis of the myocyte (Lindner, 1957). These tubules occur 
periodically with regular spacing of approximately 2 µm and are anchored along sarcomeric Z-
discs. They have a variable diameter of 200 to 400 nm (Fawcett and McNutt, 1969; Kostin et 
al., 1998; Savio-Galimberti et al., 2008; Soeller and Cannell, 1999; Wagner et al., 2012). In the 
1970s, axially orientated membrane structures were detected for the first time in ventricular 
cardiomyocytes that interconnect transverse membranes within the cytoplasm (Sperelakis and 
Rubio, 1971) revealing a highly complex system of elongated membranes, called the 
transverse-axial tubule system (TATS) (Forbes et al., 1984). It has been estimated that the 
TATS is composed of 60% transverse and 40% axial membranes (Soeller and Cannell, 1999). 
Like in skeletal myofibers, also in cardiomyocytes membrane tubules are highly associated 
with the SR. Contrastingly, one transverse or axial tubule of the TATS is in close vicinity to only 
one terminal cisterna of the SR, an association called therefore cardiac dyad. The membranes 
of those two organelles are separated by a narrow cleft of approximately 15 nm (Cannell et al., 
2006; Fawcett and McNutt, 1969; Nelson and Benson, 1963; Rostgaard and Behnke, 1965). 
The cardiac dyad is the contact site of voltage-gated Ca2+ channel CaV1.2 located at transverse 
and axial mambranes of the TATS and the Ca2+ sense and release channel ryanodine receptor 2 
(RyR2) at the membrane of the cardiac SR (Pinali et al., 2013; Swift et al., 2012). In 
cardiomyocytes contraction is initiated by a mechanism called Ca2+-induced Ca2+ release 
(CICR). The sarcolemma of cardiomyocytes gets depolarized through electrochemically 
propagation of the action potential from adjacent cells. Due to its continuity with the plasma 
membrane, also the membrane of the TATS gets depolarized leading to activation and opening 
of CaV1.2. An initial influx of Ca
2+ from the extracellular space through CaV1.2 triggers the 
opening of RyR2 and consequently the massive release of Ca2+ from the SR into the cytoplasm 











 release in cardiomyocytes.  Scheme showing a cardiac dyad and the 
increase of cytoplasmic Ca
2+
 as result of electric stimulation in cardiomyocytes. The sarcolemma of a 
cardiomyocyte gets depolarized through electrical coupling with adjacent myocytes. The depolarization 
propagates along the membrane of the transverse-axial membrane system and leads to opening of the 
cardiac voltage-gated Ca
2+
 channel CaV1.2. The moderate influx of Ca
2+
 from the extracellular space 
triggers opening of the cardiac Ca
2+
 sense and Ca
2+
 release channel RyR2 resulting in massive flow of 
Ca
2+
 from the SR into the cytoplasm of the cardiomyocyte. 
 
1.3 Other functions of tubule system 
Besides its direct importance for EC coupling, the T-tubule system functions in muscle fatigue, 
muscle differentiation, intracellular trafficking and plasma membrane repair. Experimental 
osmotic shock, for instance by treatment of single myofibers with glycerol, leads to tubule 
vacuolization with increase in tubule volume and partial detachment of T-tubules and tubule-
derived vacuoles from the sarcolemma. Vacuolization was also observed after fatigue 
stimulation by induced contraction of Xenopus laevis myofibers (Krolenko and Adamian, 2000; 
Krolenko et al., 1998; Lännergren et al., 1999). Vacuolization is reversible and highlights the 
plasticity of the T-tubule system, a characteristic which may be important for water balance, 
transport and  recovery from fatigue of skeletal myofibers (Krolenko and Lucy, 2001; Krolenko 
et al., 1998). Furthermore, the T-tubule system seems to serve as a membrane reservoir for 
the repair of membrane ruptures. The process involves protein-assisted recruitment of tubule-
derived membranes to the sarcolemma wound (Fuson et al., 2014; Klinge et al., 2007; Lek et 
al., 2013). The TATS in cardiomyocytes possesses membrane folds creating a local slow 
diffusion zone for ions and thereby separating it from the bulk extracellular space. Through 





upon concentration changes around the myocytes, decreasing the risk for arrhythmias (Hong 
et al., 2014).  
 
1.4 Biogenesis of the tubule system 
Until now, the process of T-tubule development is only poorly understood. Several models 
exist which amongst others describe the biogenesis of T-tubules as an endocytosis-like 
mechanism with tubules deriving from the plasma membrane (Ishikawa, 1968). Another 
model suggests the formation of tubules by addition of newly synthesized vesicles similar to 
the process of exocytosis (Schiaffino et al., 1977). Short tubules are first detected in the 
chicken skeletal muscle at embryonic day 14, being continuous with the plasma membrane 
and showing a longitudinal orientation along the myotube at E15 (Flucher et al., 1993). 
Subsequently, at E16, a mainly longitudinal tubule network fills the whole myofiber. The SR 
develops and associates earlier with myofibrils then the tubule system. At E15 SR and tubule 
membrane attach to each other. The formation of the triads, at which from now on EC 
coupling occurs (Flucher et al., 1993), goes hand in hand with the translocation of CaV1.1 from 
the sarcolemma to membrane tubules (Romey et al., 1989). Much later during embryonic 
development, transverse branches are formed. The mature transverse structure of the T-
tubule system is reached not earlier than several weeks after hatching (Flucher et al., 1993). 
Same is true for the biogenesis of the T-tubule system in mice. At birth, orientation of tubules 
is mainly longitudinal with some transverse connection. Final maturation is accomplished 
within the first 2 weeks of life (Franzini-Armstrong, 1991; Takekura et al., 2001). The exact 
molecular mechanism of T-tubule biogenesis is under investigation. Still, some proteins, 
including bridging integrator 1, junctophilin 2, caveolin 3 and dysferlin, have been directly 
implicated in this process. 
 
1.5 Caveolin 3 
Caveolins (CAVs) are the proteinaceous component and creators of flask-shaped plasma 
membrane invaginations with a size of 60 to 80 nm, the caveolae. Caveolae specifically 
function in several processes, such as signal transduction and lipid regulation (Parton and 
Simons, 2007), but also are involved in the development of the tubule system as first proposed 
in 1968 (Ishikawa, 1968). One of the CAV proteins, CAV3, is mainly expressed in the striated 
muscle (Tang et al., 1996). CAV3 expression is specifically induced during differentiation of the 





shown by colabeling with CaV1.1 (Parton et al., 1997; Tang et al., 1996). Depletion of CAV3 in 
mice is accompanied by alterations of the skeletal T-tubule system with dilation and 
longitudinal orientation of tubules (Galbiati et al., 2001). Mutations in the human CAV3 gene 
are associated with skeletal and cardiac muscle diseases: autosomal dominant limb-girdle 
muscular dystrophy type 1C (LGMD1C, OMIM #607801), rippling muscle disease (OMIM 
#606072), familial hypertrophic cardiomyopathy (OMIM #192600) and long QT-syndrome 
(OMIM #611818) (Betz et al., 2001; Hayashi et al., 2004; Minetti et al., 1998; Vatta et al., 
2006).  
 
1.6 Junctophilin 2 
Junctophilins (JPHs) 1 and 2 in skeletal and heart muscle, respectively, have a C-terminal 
transmembrane domain which is anchored in the SR membrane and an N-terminal 
phospholipid binding domain with specific affinity for the membrane of the tubule system 
(Takeshima et al., 2000). The physical bridging of terminal SR membrane with T-tubule 
membrane by JPHs is a critical step during T-Tubule biogenesis as it occurs simultaneously with 
postnatal tubule maturation and strongly enhances EC coupling efficiency (Chen et al., 2013; 
Ziman et al., 2010). Cardiac-specific knockdown of JPH2 in mice is associated with the 
development of heart failure and reduced CICR due to improper dyad formation (van Oort et 
al., 2011). JPH1 deficiency in mice is lethal at birth. Muscles of embryos and neonatal mice 
show dramatic alterations in triad morphology, which is characterized by a reduced number of 
triads and by an increased junctional SR volume.  
 
1.7 BIN1 
The human BIN1 gene encompasses 20 exons which can be spliced into several tissue-specific 
isoforms of the protein bridging integrator 1 (BIN1, Amphiphysin 2). Isoform 8 is expressed 
only in the skeletal muscle and includes the muscle-specific exon 11 (Wechsler-Reya et al., 
1997), whereas inclusion of exon 13 is specific for the cardiac form. The N-terminal part of 
BIN1 including an amphipathic helix and the BAR domain, is able to form a crescent-shaped 
dimer with itself or with the N-terminus of amphiphysin 1 (Peter et al., 2004; Wigge et al., 
1997a). The muscle-specific exon 11 encodes a short sequence called phosphoinositide (PI) 
binding motif, which increases the binding affinity of BIN1 towards phospholipids (Fugier et al., 
2011). An Src homology 3 (SH3) domain is part of all BIN1 isoforms (Ramjaun and McPherson, 





binds the BAR and PI domains intramolecularly and competes with the phospholipid 
phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2). The presence of PI(4,5)P2 and binding to 
BAR and PI domains induce a conformational change of BIN1 and the release of the SH3 
domain from BAR and PI binding. Subsequently, the SH3 domain can interact with proteins 
exhibiting an adequate proline-rich motif such as the GTPase dynamin 2 on PI(4,5)P2-enriched 
membranes (Kojima et al., 2004). Amphiphysins are reported to play a role during the process 
of endocytosis in neuronal and non-neuronal cells through interaction with proteins such as 
dynamin which are associated with clathrin-coated pits (Bauerfeind et al., 1997; David et al., 
1996; Shupliakov, 1997; Wigge et al., 1997b). It is assumed that BIN1 mediates the recruitment 
of effector proteins to the site of membrane fission during the endocytic process (Taylor et al., 
2011).  
BIN1 is reported to be involved in T-tubule biogenesis. It localizes to the developing T-tubule 
system in skeletal and heart muscle (Hong et al., 2010; Lee et al., 2002). The protein induces 
the formation of membrane invaginations and cytosolic tubules that are continuous with the 
plasma membrane upon heterologous expression in CHO cells and myoblasts. The BIN1 
protein directly tubulates liposomes in vitro (Lee et al., 2002). This function is considered as 
analogous to membrane reorganization events during development of the T-tubule system. A 
direct sculpting function of BIN1 for the cardiac TATS has been established in recent years. 
BIN1 shapes the tubule system and generates microfolds of the T-tubule membrane leading to 
low ion diffusion inside the tubule. The separation of these microdomains from the bulk 
extracellular space is possibly a mechanism to protect the heart from arrhythmias (Hong et al., 
2014). By forming these folded membranes, BIN1 assembles CaV1.2 molecules to form CaV1.2 
clusters at the tubule membrane. Furthermore, BIN1 regulates Ca2+ channel trafficking and 
assembly by attracting and anchoring CaV1.2 molecules that are delivered via microtubule-
mediated transport from the Golgi network to the tubular membrane (Hong et al., 2010). 
Upon activation of β-adrenergic receptor signaling BIN1 recruits phosphorylated RyR2 into 
dyads, thereby increasing Ca2+ release (Fu et al., 2016). An abnormally formed T-tubule system 
has been detected in Drosophila melanogaster upon gene knockout (Razzaq et al., 2001), in 
adult mouse skeletal muscle fibers after BIN1 knockdown (Tjondrokoesoemo et al., 2011) and 
in human muscle biopsies of BIN1-deficient patients (Toussaint et al., 2011). Reduced 
expression of BIN1 is detected in heart failure leading to impaired trafficking and clustering of 
CaV1.2 and RyR2 at cardiac dyads. Finally, contractility is reduced and arrhythmogenic risk is 
increased due to RyR2 uncoupling and Ca2+ leaks from the SR (Fu et al., 2016; Hong et al., 





recessive centronuclear myopathy (ARCNM, OMIM #255200) characterized by early disease 
onset, a proximal slowly progressive skeletal muscle weakness and centralized nuclei (Böhm et 
al., 2010, 2013, 2014; Claeys et al., 2010; Nicot et al., 2007).  
 
1.8 Dysferlin 
The DYSF gene encodes the 230 kDa protein dysferlin which belongs to the ferlin protein 
family (Anderson et al., 1999; Matsuda et al., 1999). The ferlins are named after their 
homology to the Caenorhabditis elegans protein Fer-1 that is essential for fusion of 
membranous organelles to the sperm plasma membrane during spermiogenesis (Achanzar 
and Ward, 1997). Human orthologs of dysferlin are myoferlin, otoferlin and Fer-1-like protein 
5 (FER1L5). Otoferlin plays a role in exocytosis of synaptic vesicles in the inner ear hair cells 
and is crucial for Ca2+-dependent fusion of vesicles to the plasma membrane (Ramakrishnan et 
al., 2014). Mutations in the gene encoding otoferlin and leading to a nonfunctional or absent 
protein result in nonsyndromic deafness (Yasunaga et al., 2000). Myoferlin is highly expressed 
in myogenic precursor cells during differentiation and plays a crucial role during myoblast-
myoblast and myoblast-myotube fusion (Doherty et al., 2005). Until now, no pathogenic 
mutations have been described for the genes encoding myoferlin and FER1L5. All ferlins are 
type II transmembrane proteins and have a similar domain structure. Besides a C-terminal 
transmembrane domain, a DysF sequence and ferlin domains, they possess multiple C2 
domains (Davis et al., 2002) (Figure 4). C2 domains, like the proteinkinase C C2 domains, 
mediate Ca2+-dependent membrane binding via phospholipid interaction (Coussens et al., 
1986). The ferlin C2 domains are diverse as each C2 domain is more similar to its 
corresponding domain in paralogs than to the other C2 domains in the same ferlin 
(Washington and Ward, 2006). This indicates distinct domain functions within one protein. The 
C2A domain of dysferlin binds phosphatidylinositol-4-phosphate (PI(4)P) and PI(4,5)P2, a 
phospholipid that is enriched in the membrane of the T-tubule system, in a Ca2+-dependent 







Figure 4 | Structural characteristics of C2 domain proteins.  (A) Protein domain structure of Fer-1 and 
mammalian ferlin-like proteins showing high similarity. (B) Phylogenetic tree based on alignment of 
individual ferlin C2 domain sequences. Adapted from Han & Campbell, 2007. 
 
Dysferlin´s single transmembrane domain is located at the extreme C-terminus (13 amino 
acids upstream of the C-terminus), characterizing dysferlin as a tail-anchored (TA) protein 
(Borgese et al., 2003a). The large N-terminal part is directed into the cytosol and the very 
short C-terminus is protruded into the extracellular space or organelle lumen (Kerr et al., 
2013). Many integral membrane proteins initially pass the ER before being transported to the 
plasma or organelle membrane (Shao and Hegde, 2011). Due to the domain topology, TA 
proteins cannot be integrated into the membrane of the ER by the classical co-translational 
signal recognition particle (SRP)-dependent pathway involving the Sec61-complex (Borgese et 
al., 2003b; Kutay et al., 1993). As the transmembrane domain is located at the extreme C-
terminus it emerges from the ribosome just prior to completion of translation. The mechanism 
for TA insertion includes both, a cytosolic component shielding the hydrophobic 





integrating the protein into the membrane (High and Abell, 2004). The conserved pathway 
required for the insertion of TA proteins involves the cytoplasmic chaperone ATPase 
transmembrane domain recognition complex 40 kDa (TRC40/Asna-1) which posttranslationally 
interacts with the C-terminal hydrophobic stretch of the TA protein (Favaloro et al., 2008; 
Stefanovic and Hegde, 2007). TRC40 delivers the TA protein to the ER membrane-integrated 
receptor complex consisting of WRB (Tryptophan Rich Basic protein) and the mammalian 
specific CAML (Calcium signal-modulating cyclophilin ligand) (Vilardi et al., 2011; Yamamoto 
and Sakisaka, 2012) which leads to subsequent insertion into the ER. The nature of dysferlin as 
a TA protein suggests that it might be integrated into the ER before trafficking to its target 
membrane. Though, it is not known whether and how dysferlin enters the ER on its way 
through the cell. It is suggestive that the long N-terminal stretch of dysferlin is interacting with 
chaperones during translation to ensure accurate folding of the protein. Also, the hydrophobic 
transmembrane domain emerging from the ribosome at the end of translation has to be 
shielded be chaperones to avoid aggregation.  
 
1.9 Dysferlin function 
The best characterized role of dysferlin is its function in membrane repair. The skeletal muscle 
is able to adapt to functional requirements like repetitive and continuous contractions. 
Therefore, the plasma membrane needs to be both, flexible and robust, as it is stressed by 
myofiber contractions. Still, small membrane ruptures, so called microlesions, can occur upon 
exceeded stress and have to be repaired immediately to protect the cell from massive Ca2+ 
influx and Ca2+-induced cell damage (Reviewed in (Tidball, 2011)). Upon entry of Ca2+ into the 
cell, several processes conglomerate in the accumulation of vesicles and other membraneous 
organelles to form a membrane patch which seals the ruptured plasma membrane by fusion of 
vesicles with each other and with the sarcolemma (Allen et al., 2010; McDade and Michele, 
2014). Ultrastructural analysis of damaged dysferlin-deficient myofibers reveals disruption of 
the plasma membrane and subsarcolemmal accumulation of vesicles indicating diminished 
ability of vesicles to fuse and repair membrane lesions (Bansal et al., 2003; Cenacchi et al., 
2005; Selcen et al., 2001). Direct disruption of the plasma membrane repair mechanism due to 
dysferlin-deficiency was reported for skeletal and heart muscle in mouse and human (Bansal 
et al., 2003; Han et al., 2007; Lostal et al., 2012; Philippi et al., 2012). In dysferlin-competent 
myofibers the membrane repair process is dependent on the orchestrated interaction of 
several proteins, of which dysferlin is a key player. Upon membrane rupture, initially, 





2009; Matsuda et al., 2012). Subsequently, dysferlin-containing vesicles arrive strongly Ca2+-
dependently together with cytoplasmic annexin A6 at the membrane lesion and form a tight 
patch (McDade et al., 2014; Roostalu and Strähle, 2012). It has been shown that not the full-
length dysferlin is directly involved in membrane repair. Instead, dysferlin is Ca2+-dependently 
cleaved by calpains resulting in a so called mini-dysferlinC72 peptide that is decorating the 
accumulating injury-induced vesicles (Lek et al., 2013; Redpath et al., 2014) (Lek et al., 2013). 
Finally, vesicle fusion is induced by dysferlin-dependent recruitment of annexin A2 and A1 
(Lennon et al., 2003). 
In addition to membrane repair, dysferlin is involved in other processes of the myofiber that 
involve vesicle trafficking and fusion such as cytokine and receptor exocytosis (Chiu et al., 
2009; Demonbreun et al., 2011). This function is supported by the observation that dysferlin´s 
C2A and C2B domain interact with α-tubulin and microtubules in the skeletal muscle (Azakir et 
al., 2010).  
 
1.10 Dysferlin´s involvement in T-tubule biogenesis 
In addition to the above mentioned indications such as analogy to the membrane modeling 
Fer-1 and binding to PI(4,5,)P2, further observations point to the involvement of dysferlin in 
the biogenesis of the T-tubule system in skeletal muscle. Dysferlin expression can be detected 
at the earliest stages of human development examined at 5 - 6 weeks of embryonic age, the 
stage when regional differentiation of the limbs can be detected (Anderson et al., 1999). 
Thereby, dysferlin localizes to the plasma membrane and especially the T-tubule system 
(Ampong et al., 2005; Anderson et al., 1999; Klinge et al., 2008). In differentiating myotubes 
dysferlin associates with the developing T-tubule network and is only recruited to plasma 
membrane lesions upon muscle fiber injury (Klinge et al., 2007). In addition to localization at 
the adult skeletal T-tubule system (Kerr et al., 2013), dysferlin shows localization at T-tubules 
in regenerating myofibers and only in later stages of regeneration it translocates to the 
sarcolemma (Klinge et al., 2010a). This lead to the suggestion that dysferlin is involved in T-
tubule development of the skeletal muscle. Further evidence for this hypothesis was provided 
by the observation of a highly abnormally configured T-tubule system with dilated and 
longitudinally orientated tubules in predystrophic dysferlin-deficient mice (Klinge et al., 2010a) 
and increased sensitivity of the T-tubule system upon damage (Demonbreun et al., 2014; Kerr 
et al., 2013). Recent work of our group uncovers a direct shaping role of dysferlin during 
biogenesis of the skeletal T-tubule system (Hofhuis et al., 2017). Upon heterologous 





depletion of these structures by cholesterol suggests that they are composed of membrane 
probably deriving from the plasma membrane. Additionally, dysferlin protein alone is capable 
of tubulating liposomes in vitro. Comparison of dysferlin and BIN1 revealed that the 
mechanism underlying tubulation is distinct. While BIN1-induced tubulation is dependent on 
the GTPase dynamin 2, dysferlin tubulates membranes independently of dynamin 2. 
Furthermore, the recent work links dysferlin-induced tubulation necessarily to the 
phospholipid PI(4,5)P2, which is enriched in the T-tubule membrane. The tubulation ability of 
dysferlin is abrogated by pathogenic mutations emphasizing that this function is 
physiologically relevant (Hofhuis et al., 2017). 
 
1.11 DYSF gene and mutations 
The DYSF gene is located on chromosome 2p13 and encompasses 55 exons (Liu et al., 1998). 
DYSF is conserved among mammals with a sequence similarity of 90% between the human 
and mouse gene (Vafiadaki et al., 2001). 80 recurrent mutations, occurring in at least three 
unrelated patients, are described for the DYSF gene (UMD-DYSF mutations database, 
http://www.umd.be/DYSF/W_DYSF/mutation.html). Mutations include mainly point 
mutations and small insertions or deletions and cover the entire coding region without any 
mutational hotspot regions. No genotype-phenotype correlation with respect to the distinct 
clinical manifestations exists (Klinge et al., 2008, 2010b; Krahn et al., 2009). Approximately a 
quarter of DYSF mutations comprise nonsense mutations that lead to the generation of a 
premature termination (stop) codon. Dysferlin mutations may lead to degradation of the 
altered mRNA through nonsense-mediated mRNA decay (Fujita et al., 2007) or mutant protein 
aggregation (Wenzel et al., 2006), thus causing total absence or reduction and altered 
localization of the protein, respectively. One patient has been identified with a truncated 
variant of dysferlin composed of the transmembrane domain, the last C2 domains and an out-
of-frame N-terminal sequence. This patient showed late onset of disease and moderate 
progression compared to other dysferlin-deficient patients (Krahn et al., 2010).  
 
1.12 Dysferlinopathy 
Muscular dystrophies are a heterogeneous group of inherited muscle diseases characterized 
by progressive wasting and weakness of skeletal muscles. The age of disease onset is very 
variable spanning from late childhood to adolescence. Dystrophic muscle is designated by 





substitution of muscle tissue by fat and connective tissue (Flanigan, 2012). Dysferlin-deficient 
muscular dystrophy (Dysferlinopathy) is a rare disease (incidence 1/100,000 – 200,000,(Moore 
et al., 2006) caused by mutations in the DYSF gene and comprises mainly three clinically 
distinct skeletal muscle disorders: autosomal recessive limb-girdle muscular dystrophy type 2B 
(LGMD2B, OMIM #253601, (Bashir et al., 1998), Miyoshi myopathy (MM, OMIM #254130(Liu 
et al., 1998) and distal anterior compartment myopathy (OMIM #606768, (Illa et al., 2001). 
Until now, no curative treatment is available. Initial symptoms occur mostly in the first or 
second decade of life and involve muscle weakness and pain in the proximal or distal limb 
muscles for LGMD2B and MM, respectively. Additionally, a massive increase of serum creatine 
kinase levels is detectable indicating destruction of muscle tissue (Linssen et al., 1997; 
Mahjneh et al., 1996; Weiler et al., 1999). The diagnosis of dysferlinopathy is based on strongly 
reduced or absent expression of dysferlin protein in muscle biopsies and subsequent 
confirmation by genetic analysis. The disease course of dysferlin-deficiency is typically slowly 
progressive with propagation of the symptoms and dystrophic changes to other then primarily 
affected muscle groups, finally leading to affection of all limb-girdle muscles (Nguyen et al., 
2007). In contrast to muscular dystrophies involving defects in the dystrophin-glycoprotein 
complex (DGC) with instability of the plasma membrane (Koenig et al., 1988), dysferlin-
deficient muscle maintains a functional DGC, indicating that dystrophic changes do not result 
from an instable plasma membrane structure but arise from a different pathomechanism 
(Bansal et al., 2003). Dysferlin-deficiency leads to disturbed myogenic differentiation (De Luna 
et al., 2007) and accumulation of subsarcolemmal vesicles (Cenacchi et al., 2005; Piccolo et al., 
2000). Furthermore, a diminished membrane repair capacity of dysferlin-deficient muscle has 
been reported (Bansal et al., 2003; Hofhuis et al., 2017). Taking into consideration that 
dysferlinopathy patients are without symptoms in their first decades of life and that 
restoration of membrane repair is not sufficient to prevent the dystrophic phenotype (Lostal 
et al., 2012), it consequentially eliminates the possibility that the dystrophic changes are 
exclusively caused by a defective membrane repair system (Hofhuis et al., 2017). The function 
of dysferlin in formation of membrane tubules is linked to the development of the T-tubule 
system and is defective for pathological mutants leading to the conclusion that 
dysferlinopathy is caused by the inability of mutant dysferlin to properly form the T-tubule 
system in skeletal muscle (Hofhuis et al., 2017). Interestingly, dysferlin-deficient patients show 
a high level of fitness during childhood before onset of symptoms, an observation that is 
unique among all forms of muscular dystrophy (Klinge et al., 2010b). This phenotype could be 





wheel experiment (Hofhuis et al., 2017). The explanation for increased muscle prowess upon 
dysferlin-deficiency might be an alteration in channel function due to deformation of the T-
tubule system and redistribution of dysferlin-controlled PI(4,5)P2 (Hofhuis et al., 2017).  
 
1.13 Dysferlin in the heart 
A lot of research has been performed to analyze the role of dysferlin and the effects of 
dysferlin-deficiency in skeletal muscle. Much less is known about the importance of dysferlin 
for the heart muscle. Dysferlin is mainly regarded as skeletal muscle disease because only in a 
few patients, diagnosed with dysferlinopathy, cardiac involvement is reported (Kuru et al., 
2004). As in skeletal muscle, dysferlin is also involved in membrane repair of cardiomyocytes 
and exhibits a cytoprotective function in the model of ischemia/reperfusion injury (Han et al., 
2007; Tzeng et al., 2014). The examination of mouse models for dysferlin-deficiency reveals 
that no or only a very mild cardiac phenotype is found under normal conditions (Chase et al., 
2009; Rubi et al., 2015; Wenzel et al., 2007). In contrast, excessive strain such as 
ischemia/reperfusion injury, physical stress exercise or β-adrenergic activation by 
isoproterenol treatment of mice leads to signs of cardiac dysfunction (Chase et al., 2009; Han 
et al., 2007; Tzeng et al., 2014; Wei et al., 2015; Wenzel et al., 2007). These include the release 
of creatine kinase and Evens blue dye uptake as indications of membrane damage (Han et al., 
2007; Tzeng et al., 2014), cardiac fibrosis, reduced fractional shortening (Wenzel et al., 2007), 
decreased stroke volume and relaxation velocity (Wei et al., 2015). Thus, systolic as well as 
diastolic cardiac functions are altered upon stress in dysferlin-deficient mice.  
 
1.14 Tubule system in heart failure 
Amongst the cardiovascular diseases, heart failure (HF) is one of the most frequent diseases 
leading to death. HF might be caused by chronic hypertension, acute myocardial infarction or 
ischemic heart disease and is more a secondary syndrome than a primary disease. HF is 
chronically progressive and described as condition in which heart function is decreased and 
insufficient to fulfil the metabolic demands of the body (Levy et al., 1996). HF is characterized 
by diminished cardiomyocyte contraction resulting from uncoupling of CaV1.2-RyR2 dyads and 
reduced systolic Ca2+ release (Gómez et al., 1997; Pieske et al., 1999). Several studies report 
that the cardiac TATS is altered in failing hearts and that disturbed Ca2+ handling might result 
from these morphological abnormalities. Confocal imaging of failing cardiomyocytes shows  





asynchronous EC coupling and reduced delayed Ca+2 release from the SR (Heinzel et al., 2008; 
Louch et al., 2004, 2006). In situ confocal visualization of whole hearts has the beneficial 
aspect that tissue integrity is preserved. Analysis of rat hearts from a pressure overload model 
shows that loss and redistribution of the T-tubule system starts early in compensated 
hypertrophy before progression to heart failure (Chen et al., 2015; Wei et al., 2010). Scanning 
ion conductance microscopy (SICM) provides information about the surface topology and 
reveals detachment of tubules from the sarcolemma in human and rat failing cardiomyocytes 
(Lyon et al., 2009). Detailed 3D analysis of a porcine myocardial infarction model shows loss of 
tubule structures in the peri-infarct zone and branching and axialization of remaining tubules 
(Pinali et al., 2017). Human failing cardiomyocytes show sheet-like rather than tubular 
invaginations of the sarcolemma and again decrease in T-tubule density. Additionally, Ca2+ 
release is delayed and asynchronous in cardiomyocytes from patients with HF (Seidel et al., 
2017). Asynchronity might be due to uncoupling of T-tubules from the sarcomeres and left-
behind, so called, orphaned RyRs leading to uncontrolled Ca2+ handling as shown in 
spontaneously hypertensive rats developing HF (Song et al., 2006). Cannell and colleagues 
analyzed fixed myocardium from HF patients and found redistribution of TATS with dilated and 
mainly longitudinally orientated tubules (Cannell et al., 2006). Regularity of T-tubule alignment 
was analyzed by Wei and colleagues using Fourier transformation of confocal images and 
assessment of obtained power spectra (Song et al., 2006). Therefore, whole rat hearts were 
staining with the membrane dye FM 4-64 and analyzed by confocal microscopy. The T-tubule 
power index (TTpower) revealed global reorganization of the tubule system which correlated 
with disease progression (Wei et al., 2010). 
 
1.15 Therapeutic strategies for dysferlinopathy 
Several studies have investigated different therapeutic approaches for the treatment of 
dysferlinopathy. Until now, none of these approaches could be developed into a curative 
treatment.  
 
1.15.1 Immune modulation 
Muscle inflammation with infiltration of T-cells and macrophages as well as enhanced 
phagocytic activity of peripheral monocytes is a typical sign of dysferlinopathy (Gallardo et al., 
2001; Nagaraju et al., 2008). Thus, several studies aimed to ameliorate disease progression 





deficient muscle (Gallardo et al., 2001), still Lerario and colleagues observed a slight increase 
in muscle force after depletion B-cells with Rituximab© in two dysferlinopathy patients, 
indicating that B-cells might be involved in the pathogenesis (Lerario et al., 2010). Inhibition of 
the Rho-kinase, which has a key signaling function in immune activation, using the substance 
fasudil was conducted in two mouse models of dysferlinopathy. Treatment resulted in 
suppressed immune response, but no or exacerbating muscular disease phenotype was 
observed (Rayavarapu et al., 2010). Another important signaling molecule of the inflammatory 
response, NF-ƘB, was inhibited by the treatment of dysferlin-deficient mice with celastrol for 4 
months. The muscle inflammation was reduced without a beneficial effect on physical muscle 
function (Dillingham et al., 2015). Within the framework of a clinical trial immune suppression 
of dysferlinopathy patients was achieved by treatment with the glucocorticoid deflazacort. 
This lead to severe steroid-associated side effects and no improvement or even exacerbation 
of muscle strength (Walter et al., 2013). Consequently, immunosuppression in dysferlin-
deficient muscular dystrophy seems not to be a promising therapeutic approach.  
 
1.15.2 Influencing Ca2+ homeostasis 
Dysferlin associates with Ca2+ handling proteins in the membrane of T-tubules (Ampong et al., 
2005) and contributes to the maintenance of Ca2+ homeostasis (Hofhuis et al., 2017; Kerr et 
al., 2013). Therefore, the alteration of Ca2+ handling was handled as therapeutic possibility to 
ameliorate disease progression. Dantrolene, which is binding to RyRs and thereby reducing 
Ca2+ release from the SR (Krause et al., 2004) was used to treat two patients with MM. Beside 
of a slight decrease of creatine kinase level, no positive effect was detected. Treatment of one 
patient had to be terminated prematurely because of suspected hepatopathy, a common side 
effect (Hattori et al., 2007; Montané et al., 2004). Furthermore, inhibition of CaV1.1 by 
diltiazem in dysferlin-deficient isolated myofibers and treated mice was reported to prevent 
contraction-induced membrane damage probably through reduced injury-induced Ca2+ influx 
and activation of Ca2+-mediated cytotoxicity. Diltiazem is approved for clinical use and might 
be a potential therapeutic for the treatment of dysferlinopathy  (Kerr et al., 2013).  
 
1.15.3 Gene therapy 
Another field, which is extensively investigated as therapeutic strategy for dysferlin-deficient 
muscular dystrophy, is the modulation of dysferlin expression either through import of 





approaches have been analyzed at preclinical level and seem to be promising strategies for 
further clinical development (Barthélémy et al., 2011). Delivery of coding genes into gene-
deficient organisms is a gene therapeutic approach for the treatment of genetic diseases.  
Adeno-associated virus (AAV) is currently the best vector for this purpose. Though, the 
encapsulation capacity is limited to a size of 5 kb (Pryadkina et al., 2015) and classical AAV-
meditated gene delivery of DYSF with about 6.2 kb is unfeasible. Therefore, different types of 
AAV-mediated gene delivery have been developed. Lostal and colleagues divided the DYSF 
cDNA sequence into two parts and cloned them into separate AAV vectors with appropriate 
splicing sequences. After combined intramuscular injection of both vector variants, the full-
length cDNA is generated by overlap of the two parts through homologous recombination. 
This method leads to expression of full-length dysferlin protein in the muscle leading to 
improvement of membrane capacity and locomotor activity as well as reduced dystrophic 
phenotype and necrotic fibers (Lostal et al., 2010). Safety concerns with regard to this method 
were addressed by Sondergaard and colleagues (Sondergaard et al., 2015). A comparison of 
gene transfer techniques for large genes revealed that the overlap strategy described above is 
the most effective approach in the generation of full-length dysferlin (Pryadkina et al., 2015). A 
dysferlinopathy patient with late onset and moderate disease progression was reported to 
express a so called minidysferlin, consisting of an out-of-frame N-terminal domain, the last 2 
C2 domains and the transmembrane domain (Krahn et al., 2010). Delivery of genes encoding 
truncated variants of dysferlin is technically more feasible then delivery of full-length dysferlin. 
Thus, the gene therapeutic delivery of minidysferlins is being investigated as approach to 
ameliorate the symptoms of patients with complete absence of the full-length protein. Several 
truncated dysferlin variants have been designed and analyzed for their functionality in a 
membrane wounding assay after AAV-mediated delivery showing that C2B, C2C, C2E and to a 
lesser extent C2D are not oblige for the membrane repair function (Azakir et al., 2012). 
Another gene delivery system that has been analyzed for therapy of dysferlin-deficiency is the 
Sleeping Beauty (SB) transposon system which is already used in clinical trials. It is composed 
of a synthetic non-viral vector and a transposase that can insert specific DNA fragments into 
vertebrate genomes. The advantage in comparison with AAV vectors is that DNA with more 
than 10 kB can be integrated into the target genome. Full-length dysferlin cDNA was delivered 
into dysferlin-deficient myoblasts resulting in proper protein expression. Subsequently, 
dysferlin-expressing myoblasts were successfully transplanted into a skeletal muscle of 





Often, DYSF mutations lead to reading frame shifts or the generation of premature stop 
codons leading to truncated and dysfunctional proteins that are prone for degradation. In the 
exon skipping approach, mutated mRNA is targeted and the exon harboring a highly 
pathologic mutation is removed by alternative splicing. Though, only exons, which are not 
essential for protein function, can be targeted.  The in-frame suppression of a certain exon or 
multiple adjacent exons is achieved by the application of antisense oligonucleotides (AON) 
(van Ommen et al., 2008). Currently, this approach seems to be promising for the treatment of 
Duchenne muscular dystrophy with mutations in the dystrophin-coding gene (Niks and 
Aartsma-Rus, 2017; van Ommen et al., 2008). A patient with late-onset mild dysferlinopathy 
due to a mutation leading to natural skipping of exon 32 has been reported. In this case, the 
loss of one DYSF exon leads to a mild phenotype suggesting that the function of dysferlin is not 
completely abrogated. This hints to the idea that DYSF exons may be dispensable or their lost 
causes only a mild disease phenotype (Sinnreich et al., 2006). Therapeutic exon skipping is 
optimal to target mutations that are homozygous to obtain maximal protein expression. 
Increase of wild-type dysferlin protein level to 10% in an originally dysferlin-deficient myofiber 
seems to be enough to partially ameliorate the disease phenotype. This suggests that the exon 
skipping approach might also be beneficial for heterozygous mutations if one allele is not 
targetable by this approach and normal dysferlin levels cannot be obtained (Aartsma-Rus et 
al., 2010; Sinnreich et al., 2006). AON-induced exon skipping in human myoblasts was efficient 
and led to rescue of myoblast fusion deficiency and disturbed membrane repair supporting 
this therapeutic approach (Barthélémy et al., 2015; Wein et al., 2010).  
 
1.15.4 Reallocation of mutated dysferlin 
Mutations in the DYSF gene might lead to alterations in protein structure and folding, ER 
homeostasis, trafficking and stability causing dysfunctionality and mislocalization of the 
protein (Fujita et al., 2007; Wenzel et al., 2006). Schoewel and colleagues developed dysferlin-
derived fluorescently-tagged peptides and introduced them through coupling to the cell 
penetrating peptide TAT (trans-activator of transcription from human immunodeficiency virus 
type 1) either into C2C12 cells transfected with mutant dysferlin or primary patient myoblasts. 
This strategy resulted in reduced ER stress response, localization of mutant dysferlin at the 






1.16 Translational readthrough 
One therapeutic approach for the treatment of genetic diseases caused by premature stop 
codons is the application of aminoglycosides, their derivatives or other small molecules which 
are able to induce translational readthrough of stop codons. Instead of translational 
termination the incorporation of an amino acid at the position of the premature stop codon 
takes place leading to continued translation until the original stop codon is reached and 
production of the full-length protein (Yang et al., 2016).  
 
 
Figure 5 | Aminoglycoside-induced readthrough therapy of diseases caused by nonsense mutations.  
Translation of the mRNA encoded by a gene without premature stop codons leads to the generation of 
a functional full-length protein (top). Nonsense mutation causes the premature termination of 
translation and generation of a truncated, probably unfunctional and/or degradation-prone protein. 
Aminoglycosides induce translational readthrough of a premature termination codon, thereby leading 
to continuation of translation and the generation of a full-length protein with a probable exchanged 
amino acid at the position of the premature stop codon. 
 
The concept of translational readthrough as a therapeutical approach for genetic diseases with 
premature stop codons was initially investigated for cystic fibrosis applying the 
aminoglycosides G418 (geneticin) and gentamicin (Bedwell et al., 1997; Howard et al., 1996). 
This approach is also under investigation for the treatment of Duchenne and Becker muscular 
dystrophy (Barton-Davis et al., 1999; Loufrani et al., 2004) as approximately 10% of patients 
harbor a nonsense mutation in the gene encoding dystrophin (UMD TREAT-NMD DMD 





narrow therapeutic window and dosage has to be assessed very carefully upon systemic 
administration due to oto- and nephrotoxicity. Therefore, studies developing new readthrough 
inducing substances with less adverse effects are ongoing. 




2. Aims of this work 
For a long time, dysferlin had been mainly described as mediator of muscle membrane repair 
(Bansal and Campbell, 2004; Cai et al., 2009; Lek et al., 2013). Though, a defective membrane 
repair caused by dysferlin-deficiency cannot be the only pathomechanism of dysferlin-
deficient muscular dystrophy (Bansal et al., 2003). This assumption is supported by the 
observation that the restoration of membrane repair in dysferlin-deficient myofibers does not 
impede disease progression (Krahn et al., 2010) and patients are asymptomatic and above-
average athletic until the second decade of life (Klinge et al., 2010b). In the recent years, new 
evidence supports an additional role of dysferlin during the biogenesis of the T-tubule system. 
The tubulation of membranes into elongated structures is proposed to be the primary cellular 
function of dysferlin. Mutations, which are found in dysferlinopathy patients, interfere with 
the tubulation capacity of dysferlin leading to the hypothesis that the inability of mutated 
dysferlin to tubulate membranes results in an abnormal T-tubule system and is the primary 
cause of muscular dysfunction (Hofhuis et al., 2017). Dysferlin localizes to the skeletal muscle 
T-tubule system and is essential for proper T-tubule formation in skeletal muscle (Klinge et al., 
2010a), but the exact mechanism of dysferlin´s T-tubule shaping function is unknown. Thus, 
the aims of this study were the following: The cellular fate of normal and mutated dysferlin 
should be investigated to get insight into the possible mechanisms of T-tubule formation and 
to understand the pathological events leading to muscular dysfunction. The effect of dysferlin-
deficiency should be further analyzed in a human model of early myogenesis to uncover the 
primary alterations resulting from the loss of dysferlin. Dysferlin is also highly expressed in the 
heart muscle and dysferlin-deficient mice show signs of cardiac dysfunction under stress 
conditions (Chase et al., 2009; Han et al., 2007; Tzeng et al., 2014; Wei et al., 2015; Wenzel et 
al., 2007). Thus, the involvement of dysferlin in the biogenesis of the cardiac T-tubule system 
and the effects of dysferlin loss on the morphology of this cellular compartment should be 
investigated. As little is known about the pathomechanism of dysferlinopathy, no curative 
treatment is available. Therefore, this thesis aimed to address two different approaches, the 
stabilization of mutated dysferlin and the induction of full-length protein expression by 
translational readthrough, as therapeutic options for the treatment of dysferlin-deficient 
muscular dystrophy.  




3 Materials and Methods 
3.1 Materials 
3.1.1 Bacterial strains 
For cloning procedures and plasmid preparation the chemically competent Escherichia coli 
strain BioBlue (BIO-85036≥108cfu/μg of pUC19, Bioline GmbH) was used. 
 
3.1.2 Mammalian cell lines 
HeLa is a human epithelial cell line derived from a cervix adenocarcinoma.  
 
HEK293  is a cell line derived from human embryonic kidney cells. 
 
COS-7 cells are adherent fibroblast-like cells from the kidney of the African green monkey. 
 
CHO-K1 is an epithelial cell line derived from the ovary of the Chinese hamster.  
 
C2C12 is a murine myoblast cell line clonally derived from leg muscles of an adult C3H mouse. 
This cell line is capable of differentiating into contractile myotubes and thereby expressing 
various skeletal muscle proteins. Therefore, C2C12 cells are used in this study as model system 
for skeletal muscle differentiation.  
 
3.1.3 Human myoblasts 
Primary human myoblasts from LGMD patients and healthy controls were kindly provided by 
the Muscle Tissue Culture Collection (MTCC). I thank MTCC for providing the samples. The 
MTCC is part of the German network on muscular dystrophies (MD-NET, service structure S1, 
01GM0601) and the German network for mitochondrial disorders (mito-NET, project D2, 
01GM0862) funded by the German ministry of education and research (BMBF, Bonn, 
Germany). The MTCC is a partner of EuroBioBank (www.eurobiobank.org) and Translational 









Dysf-gene deleted mice 
B6.129-Dysftm1Kcam/J (Dysf-gene deleted) mice were kindly provided by Prof. Kate Bushby, 
Newcastle University, UK (Bansal et al., 2003)) with approval of the Mutant Mouse Regional 
Resource Centers (MMRRC), USA. Mice were housed under standard conditions and were 
treated in accordance with the European convention for the protection of vertebrate animals 
used for experimental and other scientific purposes.  
 
Rats 
Wistar rats were kindly provided by the central animal facility (Zentrale Tierexperimentelle 
Einrichtung, ZTE), University Medical Center Göttingen. 
 
3.1.5 General material and chemicals 
Table 1 | Disposables and basic material 
Materials Product number Manufacturer 
Gloves 7696900 Labsolute 
Reaction tubes, Biosphere® SafeSeal, 1.5 mL 72.706.200 Sarstedt 
Reaction tubes, Multiply®-Pro cup, 0.2 mL 72.737.002 Sarstedt 
Reaction tubes, Safe-Lock, 2 mL 30120094 Eppendorf AG 
Conical tubes, 15 mL, sterile 62.554.502 Falcon 
Conical tubes, 50 mL, sterile 62.547.254 Falcon 
Pipette filter tips 10 µL 70.111.4.210 Sarstedt 
Pipette filter tips 100 µL 70.760.212 Sarstedt 
Pipette filter tips 1250 µL, SurPhob SafeSeal®  VT0270 
Biozym Scientific 
GmbH 
Pipette tips 10 µL 70.113 Sarstedt 
Pipette tips 200 µL 70.760.002 Sarstedt 
Serological pipettes, 2 mL 86.1252.001 Sarstedt 
Serological pipettes, 5 mL 86.1253.001 Sarstedt 
Serological pipettes, 10 mL 86.1254.001 Sarstedt 
Serological pipettes, 25 mL 86.1685.001 Sarstedt 




Pasteur pipettes 7691060 Labsolute 
Parafilm®, M, laboratory film PM996 Bemis 
Filters, Minisart, pore size 0.2 µm 16534K Sigma Aldrich 
Scalpels 02.001.30.021 Feather Safety Razor 
Plates for cell culture, 35 mm  83.3900.300 Sarstedt 
Plates for cell culture, 100 mm  83.3902.300 Sarstedt 
Flasks for cell culture, 25 cm2 690175 Greiner Bio-One 
Flasks for cell culture, 75 cm2 658175 Greiner Bio-One 
Plates for cell culture, 6-well 353046 Falcon 
Plates for cell culture, 12-well 665 180 Greiner Bio-One 
Plates for cell culture, 24-well 662 160 Greiner Bio-One 
Cell flasks, NuncTM Lab-Tek® Chamber Slides 170920 
Thermo Fisher 
Scientific 
Cell dishes, µ-Slide 4 Well, ibiTreat 80426 Ibidi 
Cell dishes, µ-dish, 35 mm, glass bottom, 
ibiTreat 
81156 Ibidi 
Cell strainer, 70 µM 542070 Greiner Bio-One 
Cell scrapers 83.183 Sarstedt 
Cryo tubes, 1.8 mL 368632 Thermo Scientific 
Cryo 1°C freezing containers for cell culture 5100-0001 Nalgene 
Nitrocellulose blotting membrane, 
AmershamTM ProtranTM 0.45 µm  
10600002 GE Healthcare 
Blotting paper sheets FT-2-520-580600 K Sartorius AG 
Microplate, 96-well, flat bottom 655101 Greiner Bio-One 
Combitips advanced®, 5 mL  0030 089.456 Eppendorf AG 
Glass cover plates, 24-60 mm CS2464100 Menzel-Gläser 
Glass cover slips, 14 mm CS14100 Menzel-Gläser 
Glass microscope slides 631-0411 Menzel-Gläser 
Tubes for flow cytometry, 5 mL 352058 Falcon 
Petri dishes, 92x16 mm 82.1473.001 Sarstedt 
 




Table 2 | Instruments and equipment 
Instrument Manufacturer 
Pipette, manual, ErgoOne®,  2.5 µL, 100 µL, 200 µL, 1000 µL 
Starlab 
International GmbH 
Pipette, manual, Eppendorf Research® , 10 µL Eppendorf AG 
Pipette, manual, Pipetman® , 20 µL Gilson, Inc. 
Multipette® Plus Eppendorf AG 
Centrifuge, Universal 320, rotor 1619 
Andreas Hettich GmbH & 
Co.KG 
Centrifuge, Mikro 200R, rotor 2424-B 
Andreas Hettich GmbH & 
Co.KG 
Centrifuge, 5417R Eppendorf AG 
Centrifuge, 5424 Eppendorf AG 
Centrifuge,mini, FugeOne® Starlab GmbH 
Centrifuge, mini, Sprout Biozym Scientific GmbH 
Thermo block, TB2m Biometra  Biometra GmbH 
Thermo block, Thermostat 5320 Eppendorf AG 
Thermo block, Thermomixer compact Eppendorf AG 
Thermocycler T3 Biometra GmbH 
Thermocycler , labcycler SensoQuest GmbH 
Magnetic stirrer with temperature control 
Heidolph Instruments 
GmbH & Co.KG 
Magnetic stirrer with temperature control, Combimag RCT 
IKA®-Werke GmbH & CO. 
KG 
Vortex mixer, infrared VELP Scientifica 
Vortex mixer, Genie 2TM Bender & Hobein GmbH 
Water bath Memmert GmbH 
Weight balance Sartorius AG 




Cell culture sterile bench, HeraSafe Heraeus 




Cull culture heating plate, Culture TempTM 
Bel-Art Products, SP 
Scienceware 
Cell culture incubator, HeraCell 150 Heraeus 
Cell counting chamber, Neubauer  Brand GmbH + Co KG 
Homogenizer tissue ruptor Qiagen 
Light microscope Nikon ECLIPSE TS100 
Epifluorescence microscope, Axioimager M1, Plan Neofluar 
100x/1.3 oil lens 
Carl Zeiss AG 
Camera for epifluorescence microscope, AxioCam HRm Carl Zeiss AG 




Camera for confocal microscope, F-View II CCD  
Olympus Deutschland 
GmbH 
Confocal microscope, LSM 710 NLO, 63x/1.4 NA oil objective Carl Zeiss AG 
Spectrophotometer, ND-1000  NanoDropTM 
Power supply Consort bvba 
Power supply, Standard PowerPack P25 Biometra GmbH 
Agarose gel documentation system BioDocAnalyze 
Incubator, shaking, for bacterial cultures Memmert GmbH 
Microplate reader, BioTek Synergy Mx + power supply BioTek® Instruments 
Electrophoresis systems for SDS-PAGE, Mini-PROTEAN Tetra Cell 
Bio-Rad Laboratories 
GmbH 
Electrophoresis systems for agarose gels Analytik Jena 
Semi-dry blotting system, Biometra Fast Blot Biometra GmbH 
Western blot documentation system, LAS-4000 Fujifilm Europe GmbH 
Tube roller, SRT6, Stuart Cole-Parmer 
Rocking platform 
GFL Gesellschaft für 
Labortechnik mbH 
Rocking platform Biometra GmbH 
  




Table 3 | Chemicals and reagents 
Chemical/reagent Product number Manufacturer 
2-Propanol 1096341000 Merck KGaA  
4',6-diamidino-2-phenylindole (DAPI) 32670 Sigma-Aldrich Chemie GmbH 
4-phenylbutyric acid (PBA) P21005 Sigma-Aldrich Chemie GmbH 
Acetic acid 6755 Carl Roth GmbH + Co. KG 
Acrylamide solution, 30% with 0.8% 
bisacrylamide 
3029.1 Carl Roth GmbH + Co. KG 
Agarose Bio-41025 Bioline GmbH  
Ammonium persulfate (APS) 113H0315 Serva Electrophoresis GmbH  
Ampicillin Sodium Salt A9518-25G Sigma-Aldrich Chemie GmbH 
BCA Assay Reagent A UP95424A Interchim 
BCA Assay Reagent B UP95425A Interchim 
Bovine serum albumin (BSA), Fraktion V 8076.2 Carl Roth GmbH + Co. KG 
Bromophenol blue 8122-5g Merck KGaA  
cOmplete™ Protease Inhibitor Cocktail 
Tablets, EDTA-free 
04693116001 
Roche Deutschland Holding 
GmbH 
DiIC16(3) D384 Molecular Probes® 
Disodium phosphate (Na2PO4) T877 Carl Roth GmbH + Co. KG 
Dithiothreitol (DTT) 20710 Serva Electrophoresis GmbH  
Dimethyl sulfoxide (DMSO) 39757 Serva Electrophoresis GmbH  
Dulbecco's Modified Eagle Medium 
(DMEM), 1 g/L  D-glucose 
F 0415 Biochrom GmbH 
DMEM, 4.5 g/L  D-glucose F 0445 Biochrom GmbH 
Ethanol 1.00983.2500 Merck KGaA  
Ethylene glycol tetraacetic acid (EGTA) 3054.2 Carl Roth GmbH + Co. KG 
Ethylenediaminetetraacetic acid (EDTA) CN06.1 Carl Roth GmbH + Co. KG 
Fetal bovine serum (FBS), Gold A15-151 PAA Laboratories 
Geltrex A-14133-02 Gibco  
GeneRuler™, DNA Ladder Mix SM0331 Fermentas Life Science 
Gentamicin HN09.2 Carl Roth GmbH + Co. KG 




GlutaMAX™ -I (100x) 35050-061 Gibco 
Glycerol, anhydrous A3552 Applichem 
Horse serum 26050088 Gibco 
Hydrochloric acid (HCl) 1003141000 Merck KGaA  
Laminin from Engelbreth-Holm-Swarm 
murine sarcoma basement membrane 
L2020 Sigma-Aldrich Chemie GmbH 
Lysogeny broth (LB)-medium, powdered X968.1 Carl Roth GmbH + Co. KG 
LB-Agar (lurial/Miller), powdered X969.1 Carl Roth GmbH + Co. KG 
L-glutamine solution G8540 Sigma-Aldrich Chemie GmbH 
Lumi-Light Plus Western Blotting 
Substrate 
12 015 196 001 
Roche Deutschland Holding 
GmbH 
Lumi-Light Western Blotting Substrate 12 015 200 001 
Roche Deutschland Holding 
GmbH 
Methanol 8045 J.T. Baker 
Milk powder T145.3 Carl Roth GmbH + Co. KG 
Monopotassium phosphate (KH2PO4) 3904 Carl Roth GmbH + Co. KG 
Mowiol® 4-88 Reagent 475904 Calbiochem® 
N,N,N′,N′-Tetramethylethan-1,2-diamin 
(TEMED) 
2367.1 Carl Roth GmbH + Co. KG 
NonidetTM P (NP)-40 74385 Fluka Analytical 
PageRuler™ Prestained Protein Ladder 26616 Thermo Fisher Scientific 
Paraformaldehyde (PFA), 4% in PBS 19943 1 LT Affymetrics 
PBS (Dulbecco´s PBS) for cell culture L0615-500 Biowest 
Phenylmethane sulfonyl fluoride (PMSF) A0999,0005 Applichem 
Ponceau-S solution P7170 Sigma-Aldrich Chemie GmbH 
Potassium acetate (CH3CO2K) T874 Carl Roth GmbH + Co. KG 
Saponin 4185.1 Carl Roth GmbH + Co. KG 
Skeletal Muscle Cell Growth Medium C-23060 PROMOCELL  
Sodium azide (NaN3) K305 Carl Roth GmbH + Co. KG 
Sodium bicarbonate (NaHCO3) 0965 Carl Roth GmbH + Co. KG 
Sodium cacodylate trihydrate  C4945 Sigma-Aldrich Chemie GmbH 




Sodium chloride (NaCl) 3957.1 Carl Roth GmbH + Co. KG 
Sodium dodecyl sulfate (SDS), 20% 
solution 
1057 Carl Roth GmbH + Co. KG 
Sodium hydroxide (NaOH) 6771.1 Carl Roth GmbH + Co. KG 
Sucrose 9378 Sigma-Aldrich Chemie GmbH 
Tris 5429.3 Carl Roth GmbH + Co. KG 
Triton® X 100 3051 Carl Roth GmbH + Co. KG 
Tryptan blue, 0.5% (w/v) in 
physiologocal saline 
L2143 Biochrom GmbH 
Tween® 20 8.22184.0500 Merck KGaA  
VECTASHIELD Antifade Mounting 
Medium with DAPI 
H-1200 Vector Laboratories 
β-Mercaptoethanol M3148-25ml Sigma-Aldrich Chemie GmbH 
 
 
Table 4 | Commercial kits 
Kit Product number Manufacturer 
BigDye Terminator v3.1 Cycle 
Sequencing Kit 
4337455 Thermo Fisher Scientific 
Effectene Transfection Reagent 301427 Qiagen 
NucleoSpin® Plasmid  740588 Macherey-Nagel GmbH & Co. KG 
NucleoSpin® Gel and PCR Clean-up 740609 Macherey-Nagel GmbH & Co. KG 




Table 5 | Enzymes 
Enzyme Product number Manufacturer 
AfeI R0652 New England BioLabs® Inc.  
BamHI-HF® R3136 New England BioLabs® Inc.  
DpnI R0176 New England BioLabs® Inc.  
Endo H P0702 New England BioLabs® Inc.  




KAPA HiFi DNA Polymerase 7958846001 Kapa Biosystems 
NotI R0189 New England BioLabs® Inc.  
PRECISOR High-Fidelity DNA Polymerase 1706 BioCat GmbH 
RNAse A 556746 Calbiochem® 
T4 DNA Ligase EL0014 Thermo Fisher Scientific 
Thrombin from bovine plasma T4648 
Sigma-Aldrich Chemie 
GmbH 
Trypsin/EDTA solution, 0.05%/0.02% 
(w/v) 




Table 6 | Antibodies for western blot 




Anti-dysferlin Mouse 1:500 NCL-Hamlet 
Novocastra 
Laboratories 










of hybridoma cells) 
Mouse 1:100 
 








Table 7 | Antibodies for immunofluorescence 




Anti-amphiphysin2 (BIN1) Mouse 1:100 sc-13575 
Santa Cruz 
Biotechnology, Inc. 
Anti-dysferlin Rabbit 1:300 ab124684 Abcam  
Anti-dysferlin Mouse 1:100 NCL-Hamlet 
Novocastra 
Laboratories Ltd. 




Anti-L-type Ca2+ channel 
α1C/D/F/S (D-19) 





Goat 1:200 A-21053 Life Technologies 
Anti-mouse IgG-CyTM3 Donkey 1:200 715166150 
Jackson 
ImmunoResearch Inc. 










3.1.8 Buffers and solutions 
PBS 
 137 mM  NaCl 
 2.7 mM  KCl 
 8.1 mM  Na2PO4 
1.8   KH2PO4 
pH 7.4 
 
Buffers for plasmid isolation  
P1 
 50mM   Tris/HCl, pH 8.0 
 10 mM   EDTA 
 100 µg/mL  RNAse A 
P2 
 200 mM  NaOH 
 1% (w/v)  SDS 
P3 
 3 M   CH3CO2K, pH 5.5 
 
Cell lysis buffer  
 25 mM   Tris/HCl, pH 7.4 
 150 mM  NaCl 
 5 mM   EGTA 
 2 mM   EGTA, pH 8.0 
 1% (v/v)  NP-40 
 0.1% (w/v)  SDS 





 250 mM  sucrose 
 6.2 mM  NaN3 
 10 mM   NaHCO3, pH 7.0 
 0.1 mM  PMSF 
 1x cOmplete™  Protease Inhibitor Cocktail 
 
Sucrose cacodylate buffer 
 0.1 M   sucrose 
 0.1 M   sodium cacodylate 
 pH 7.4 
 
SDS-PAGE sample buffer, 4x 
 160 mM  Tris/HCl, pH 6.8 
 8% (w/v)  SDS 
 0.01% (w/v)  bromophenol blue 
20%   β-mercaptoethanol 
20% (v/v)  glycerol 
 
SDS-PAGE buffer 
 25 mM   Tris 
 1,92 M   glycine 
 1% (w/v)  SDS 
 
Tris-buffered saline (TBS) 
 50 mM   Tris/HCl, pH 7.6 
 150   mM NaCl 
 
Transfer buffer for semi-dry western blot 
 25 mM   Tris 
 260 mM  glycine 
 20% (v/v)  methanol 
  
TRIS-Acetat-EDTA (TAE) buffer 
 40 mM   Tris/HCl, pH 8.0 
 0.1% (v/v)  acetic acid 
 1 mM   EDTA  
 
 




3.1.9 Mammalian cell culture medium  
COS-7 and CHO-K1 culture medium  
DMEM, 4.5 g/L  D-glucose 
10% (v/v) FBS 
1% (v/v) L-glutamine 
 
HEK293 culture medium  
DMEM, 4.5 g/L  D-glucose 
5% (v/v) FBS 
1% (v/v) L-glutamine 
 
HeLa culture medium  
DMEM, 1.0 g/L  D-glucose 
10% (v/v) FBS 
1% (v/v) L-glutamine 
 
C2C12 culture medium  
DMEM, 4.5 g/L  D-glucose 
15% (v/v) FBS 
1% (v/v) L-glutamine 
 
C2C12 differentiation medium  
DMEM, 4.5g/L  D-glucose 
3% (v/v) horse serum 
1% (v/v) L-glutamine 
 
Human myoblast culture medium  
Skeletal Muscle Cell Growth Medium  
10% (v/v) FBS 
1.5% GlutaMAX™ -I (100x) 








Human myoblast differentiation medium  
DMEM, 4.5g/L  D-glucose 
5% (v/v) horse serum 
 
Freezing medium for cell lines 
DMEM, 4.5 g/L  D-glucose 
20% (v/v) FBS 
1% (v/v) L-glutamine 
10% (v/v) DMSO 
 
Freezing medium for human myoblasts 
DMEM, 4.5 g/L  D-glucose 
20% (v/v) FBS 





Designed oligonucleotides were analyzed for melting temperature, self-dimerization, hetero-
dimerization and hairpin structures using using OligoAnalyzer 3.1 (Integrated DNA 
Technologies, Inc).  
 
Table 8 | Oligonucleotide for cloning 
Oligonucleotide Sequence (5’-3’) 





Table 9 | Oligonucleotides for DpnI-mediated site-directed mutagenesis 
Oligonucleotide Sequence (5’-3’) 
OST 581 CCTGGCATGGGGCCCGCGGAACATGAAGAG 
OST 582 CTCTTCATGTTCCGCGGGCCCCATGCCAGG 
 




Table 10 | Oligonucleotides for sequencing 
Oligonucleotide Sequence (5’-3’) 
IC 1 GCT CAG CTG ACG GAT GAG C 
IC 2 GAT CTC AGC CAA ATG GAA GC 
IC 3 CTC TTC ATG GAA GTG ATG C 
IC 4 GCA GCC AGA CAT CGA GC 
IC 5 CAG CCA AGA AGT GCT CCT TGG 
OST 583 CAAAGCGGAGGCCCGG 
OST 584 GCAACCTGCTCCGGCC 
OST 585 CAGGCTTCCCAGACCC 
OST 586 GGGCACAACGGGCCTC 
OST 587 CCGCCCAGCATTGTGG 
OST 603 CAT CCC CTG CAC GCT GG 
BGH reverse TAG AAG GCA CAG TCG AGG 
CMV promoter CGCAAATGGGCGGTAGGCGTG 
Citrin 3´F1 (From Thomas Weber, 
dept. of Otorhinolaryngology, UMG) 
GCG TGC AGC TCG CCG ACC ACT ACC 
 
  




3.1.11 DNA plasmids 
Table 11 | DNA plasmids 
Plasmid name Source/reference 
EGFP-DYSF-pcDNA4 (Klinge et al., 2007) 
EGFP-DYSF-ops-pcDNA4 this study 
EGFP-DYSF-L1341P-ops-pcDNA4 this study 
EGFP-DYSF-L1341P-pcDNA4 Irmgard Cierny 
EGFP-DYSF-R959W-pcDNA4 Irmgard Cierny 
PST 1596, pcDNA3.1(+)_RFP_GFP_with MCS Corinna Dickel 
PST 1902, PST1596_DYSF c.265C>T Marco Schmidt 
PST 1990, PST1596_DYSF c.331C>T Marco Schmidt 
PST 1922 , PST1596_DYSF c.610C>T Corinna Dickel 
PST 1923, PST1596_DYSF c.691C>T Corinna Dickel 
PST 1924, PST1596_DYSF c.1566C>G Corinna Dickel 
PST 1925, PST1596_DYSF c.1717G>T Corinna Dickel 
PST 1926, PST1596_DYSF c.1758C>T Corinna Dickel 
PST 1927, PST1596_DYSF c.1813C>T Corinna Dickel 
PST 1928, PST1596_DYSF c.1834C>T Corinna Dickel 
PST 1929, PST1596_DYSF c.2494C>T Corinna Dickel 
PST 1897, PST1596_DYSF c.3112C>T Marco Schmidt 
PST 1903, PST1596_DYSF c.3516_3517delTT Marco Schmidt 
PST 1930, PST1596_DYSF c.3805G>T Corinna Dickel 
PST 1931, PST1596_DYSF c.3832C>T Corinna Dickel 
PST 1899, PST1596_DYSF c.4194C>A Marco Schmidt 
PST 1932, PST1596_DYSF c.4756C>T Corinna Dickel 
PST 1933, PST1596_DYSF c.5713C>T Corinna Dickel 
PST 1934, PST1596_DYSF c.5903G>A Corinna Dickel 
 
 





Table 12 | Software 
Software Manufacturer/reference 
Axiovision 4.8, epifluorescence microscope software  Carl Zeiss AG 
Fluoview FV1000 FV10-ASW 2.0, confocal microscope 
software 
Olympus Deutschland GmbH 
ZEN 2009, confocal microscope software Carl Zeiss AG 
Imaris x64, 7.4.0, microscopy image analysis software Bitplane AG 
GraphPad Prism 4, graphing and statistics software GraphPad Software, Inc. 
SAS® University Edition, statistics software SAS Institute Software GmbH 
Fiji, image processing software (Schindelin et al., 2012) 
ImageJ, image processing software  (Schneider et al., 2012) 
Analyze Skeleton, Fiji plugin  (Arganda-Carreras et al., 2010) 
Directionality, Fiji plugin  (Liu, 1991) 
JacoP, Fiji plugin  (Bolte and Cordelières, 2006) 
  





3.2.1 Cell biology 
3.2.1.1 Cell culture 
Culture of mammalian cell lines 
For freezing purposes, cells at confluency of approximately 70% were washed with 1x PBS and 
detached by incubation with 0.5 -1 mL trypsin/EDTA for 2 min at 37 °C. Cells were 
resuspended in 10x volume of culture medium and centrifuged at 800 rpm for 5 min. The cell 
pellet was diluted in 1 mL freezing medium and transferred into cryo tubes, which were placed 
into freezing containers at -80°C overnight (o.n.) to allow slow freezing. For long-term storage, 
cryo tubes were transferred to -150 °C. For cultivation, cells were thawed in a water bath at 37 
°C and transferred into 10 ml culture medium. After centrifugation at 800 rpm for 5 min, cell-
pellets were resuspended in culture medium and seeded in culture flasks and cultivated at 37 
°C in a 5% CO2/ 95% humidity atmosphere. Depending on their confluency cells were split 1:5 
to 1:10 every 3 to 5 days. Therefore, cells were detached with 1 mL trypsin/EDTA after 
washing with 1 x PBS. Detached cells were resuspended in culture medium and seeded into 
new culture flasks.  
 
Culture of C2C12 cells 
C2C12 were cultured in culture flasks and grown at low confluency (maximum 70%) to avoid 
unintentional differentiation of cells. Differentiation of myoblasts into myotubes was induced 
at a cell confluency of 90%. Therefore, the cultivation medium was replaced with 
differentiation medium after washing once with 1x PBS. C2C12 myoblasts were differentiated 
for 5 days. The medium was replaced by fresh differentiation medium every day.  
 
Culture of human myoblasts 
Primary human myoblasts were cultured in culture flasks and grown at low confluency 
(maximum 70%) to avoid unintentional differentiation of cells. Differentiation of myoblasts 
into myotubes was induced at a cell confluency of 90%. Therefore, the cultivation medium was 
replaced with differentiation medium after washing once with 1x PBS. Human myoblasts were 
differentiated for 7 days. The medium was replaced by fresh differentiation medium every 
day.  
 




3.2.1.2 Isolation of ventricular cardiomyocytes from rats for immunofluorescence 
staining 
The isolation of ventricular rat cardiomyocytes was performed in cooperation with the group 
of Prof. Viacheslav Nikolaev, formerly department for Cardiology and Pneumology, University 
Medical Center Göttingen. Ventricular cardiomyocytes from rat hearts were isolated by 
retrograde perfusion according to the Langendorff technique (Bell et al., 2011). 11-, 14-, 17-, 
20-, 23-day old or adult rats were anesthetized with isoflurane and sacrificed by cervical 
dislocation. The hearts were extracted quickly and connected to the perfusion system by 
putting the aorta onto the perfusion cannula. Hearts were perfused with 8 mL/min at 37 °C. 
After initial perfusion with Ca2+-free buffer for 2 min, hearts were digested with collagenase 
type II (2 mg/mL, approximately 300 U/mg) in 40 µM calcium chloride for 9 min at 37 °C.  
Following perfusion, the ventricles were separated from the atria and minced in digestion 
buffer. The tissue was carefully resuspended with a 10 mL serological pipette and the 
digestion process was stopped by adding stop buffer before again resuspending. The 
cardiomyocytes were washed three times with stop buffer. Therefore, cells were allowed to 
sediment by gravity for 8 min at RT. The supernatant containing cell debris was discarded and 
cells were again resuspended in stop buffer. For immunofluorescence staining, cells were 
seeded on laminin-coated glass coverslips and incubated for 30 min at 37 °C, before 
proceeding with the staining protocol. Laminin coating was performed by incubation of glass 
cover slips with 20 µg/mL laminin in PBS at 37 °C for 2 h. Subsequently, cover slips were 
washed and allowed to dry at RT.  
 
3.2.1.3 Isolation of rat hearts for preparation of protein lysates 
11-week old rats were anesthetized by isoflurane and sacrificed by cervical dislocation. 14-, 
17-, 20-, 23-week old rats and adult rats were euthanized by carbon dioxide inhalation and 
immediate opening of the thorax. The ventricular part of the heart was separated from the 
atrial part, transferred into reaction tubes and frozen in liquid nitrogen. Ventricular heart 
tissues were stored at -80 °C until preparation of protein lysates.  
 
3.2.1.4 Transfection of cell lines 
HeLa, HEK293, COS-7 and CHO-K1 cells were transfected with plasmid DNA using Effectene 
Transfection Reagent according to manufacturer´s instructions. 48 h after transfection, cells 




were either harvested for the isolation of proteins or fixed for immunofluorescence staining. 
C2C12 cells were transfected with plasmid DNA using Viromer® YELLOW transfection reagent 
according to manufacturer´s instructions. 72 h after transfection, cells were harvested for the 
isolation of proteins. 
 
3.2.1.5 Treatments of HeLa cells 
PBA treatment 
For stabilization experiments, HeLa cells were treated with 5 mM PBA for 24 h. Therefore, the 
medium was replaced 24 h after transfection and culture medium containing PBA was added 
for another 24 h. Transfected and PBA-treated cells were used for analysis of protein steady-
state level and localization.  
 
G418 treatment 
For readthrough analysis, HeLa cells were transfected with DNA plasmids encoding dual 
fluorescence reporters. 6 h after transfection, the medium was changed to culture medium 
containing 100 µg/mL of G418 and incubated for another 18 h. 24 h after transfection, cells 
were harvested for flow cytometric analysis.  
 
3.2.1.6 Immunofluorescence staining 
Immunofluorescence staining of cell lines 
For immunofluorescence staining, HeLa cells were seeded on glass coverslips in multi-well 
plates and C2C12 cells were seeded in NuncTM Lab-Tek® Chamber Slides. 48 h after 
transfection, cells were washed once with PBS, fixed with 4% PFA by incubation for 20 min at 
RT and washed once with blocking solution (3% horse serum and 0.5% saponin in PBS). 
Following incubation in blocking solution for 30 min at RT, cells were incubated with the 
primary antibody diluted in blocking solution for 1 h at RT in a moist chamber. Cells were 
washed three times for 5 min with PBS and incubated with the secondary antibody as outlined 
above. Following washing three times for 5 min, cells were mounted with mowiol containing 
DAPI (1:2,000). Cover slips were transferred on microscope slides. NuncTM Lab-Tek® Chamber 
Slide bottoms were covered with glass cover plates. Immunofluorescence samples were 
allowed to cure at RT o.n. and were long-term stored at 4 °C. Cells were visualized by 
epifluorescence or confocal laser scanning (Inverted IX81 Olympus) microscopy using 100x or 
63x oil objectives, respectively.  




Immunofluorescence staining of mouse ventricular cardiomyocytes 
Langendorff-isolated ventricular cardiomyocytes from 8 week-old cardiomyocyte-specific 
tamoxifen inducible WRB knockout mice (MerCreMer - (Cre-) and MerCreMer + (Cre-, 
knockout)) were provided by Dr. Jhon Rivera-Monroy, department of Molecular Biology, 
University Medical Center Göttingen (For isolation protocol see Rivera-Monroy et al., 2016). 
The staining of cardiomyocytes were performed were carefully to avoid detachment of the 
cells. Cardiomyocytes were fixed with 4% PFA for 5 min at RT and washed twice with PBS 
before blocking with 10% FBS in PBS for 60 min at RT. Primary antibody was diluted in 5% 
FBS/PBS and incubated in a moist chamber at o.n. at 4 °C. After washing once for 5 min with 
PBS, incubation with the secondary antibody was performed for 1 h at RT in the dark in a 
moist chamber. Cells were washed twice for 5 min with PBS, briefly washed with water and 
mounted with mowiol containing DAPI (1:2,000). Immunofluorescence samples were allowed 
to cure at RT o.n. and were long-term stored at 4 °C. Cells were visualized by confocal laser 
scanning microscopy using a 63x oil objective. Dysferlin expression level was analyzed on the 
basis of confocal immunofluorescence images and calculated as corrected total cell 
fluorescence (CTCF) by subtracting the background multiplied with the cell area from the 
integrated cell intensity.  
 
Immunofluorescence staining of rat ventricular cardiomyocytes 
Langendorff-isolated ventricular rat cardiomyocytes were fixed in 4% PFA for 5 min at RT and 
blocked in 5% horse serum and 0.2% Triton® X 100 in PBS for 1 h at RT. Primary antibody was 
diluted in the blocking solution and incubated in a moist chamber o.n. at 4 °C. After washing 
twice shorty and once for 10 min with blocking solution, cells were incubated with secondary 
fluorescently-labeled antibody for 4 h at RT in a moist chamber. Cells were washed as 
described above with PBS and mounted with VECTASHIELD® containing DAPI. After burdening 
o.n. at RT, cells were visualized by confocal laser scanning microscopy (Inverted IX81 
Olympus).  
 
3.2.1.7 Membrane staining 
Membrane staining of human myoblasts with DiIC16(3) 
Undifferentiated human myoblasts were seeded in µ-Slide 4 Well cell dishes. After 
differentiation of 7 days, cells were washed with sucrose cacodylate buffer and incubated with 
DiIC16(3) diluted to 12.5 μg/mL in sucrose cacodylate buffer for 10 min at RT. Cells were 
visualized by confocal laser scanning microscopy (Inverted IX81 Olympus).  




Membrane staining of mouse ventricular cardiomyocytes with di-8-ANEPPS 
The isolation of ventricular cardiomyocytes from Dysf gene-deleted and control mice was 
performed by Ines Müller, group of Prof. Niels Voigt, institute of Pharmacology and 
Toxicology, University Medical Center Göttingen. Ventricular cardiomyocytes from mouse 
hearts were isolated by retrograde perfusion according to the Langendorff technique (Bell et 
al., 2011). For membrane staining, cells were gently resuspended in stop buffer containing 50 
µM di-8-ANEPPS. Immediately, cells were seeded in laminin-coated microscopy cell dishes (µ-
dish, 35 mm, glass bottom, ibiTreat) and incubated for 30 min at RT in the dark. Laminin 
coating was performed by covering the bottom of the microscopy cell dishes with 20 µg/mL of 
laminin in PBS and incubation at 37 °C for 1 h. Subsequently, cover slips were washed and 
allowed to dry at RT. After the staining, the di-8-ANEPPS solution was removed carefully to not 
detach the cells from the bottom. After washing once with stop buffer, cells were overlayed 
with stop buffer and imaged by confocal laser scanning microscopy (LSM 710 NLO equipped 
with a 63x/1.4 NA oil objective). For the imaging protocol see (Wagner et al., 2014). 
 
3.2.1.8 Analysis of TATS morphology of di-8-ANNEPS-stained mouse ventricular 
cardiomyocytes 
The confocal images of di-8-ANEPPS-stained ventricular cardiomyocytes from Dysf gene-
deleted and control mice were processed and analyzed as described by Wagner and 
colleagues (Wagner et al., 2014) with minor changes: For background subtraction, the rolling 
ball radius was set to 15. The amount of axial and transversal structures was calculated as the 
sum of structures with an orientation of -5° to +5° (axial) and +85° to +95° (transversal).  
 
3.2.1.9 Flow cytometric analysis of readthrough using dual reporter assay 
For the analysis of readthrough of stop codon contexts (stop codon +/- 10 nucleotides 
upstream and downstream) from all DYSF nonsense mutations, a dual fluorescent reporter 
was used and coupled to flow cytometric analysis of fluorescence. The dual reporter consists 
of an N-terminal TagRFP and a C-terminal EGFP tag flanking the stop codon context. A 
construct without a stop codon between the fluorescent tags served as 100% readthrough 
control. HeLa cells were transfected with the dual reporter and readthrough was either not 
induced (basal readthrough) or induced by the treatment with G418. 24 h after transfection, 
cells were harvested by trypsin/EDTA and centrifugation. The cell pellet was resuspended in 
700 µL PBS containing 10% FCS and cells were filtered through a cell strainer. The cells were 




analyzed by flow cytometry using a LSRII (Becton Dickinson) flow cytometer equipped with 
488 nm and 561 nm lasers. Living cells were selected by gating according to side scatter (SSC-
A, corresponds to cell granularity) and forward scatter (FSC-A, corresponds to cell size). 
Additionally, cells were gated according to TagRFP and EGFP fluorescence intensity by setting 
a threshold which excludes non-transfected cells. Finally, the readthrough was calculated as 
the EGFP over TagRFP fluorescence ratio normalized to the untreated 100% readthrough 
control.  
 
3.2.2 Protein biochemistry 
3.2.2.1 Isolation of proteins from cells for SDS- polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Whole cell protein lysates were obtained from confluent cell cultures. After washing once with 
PBS, 1 mL PBS was added. Cells were detached by cell scrapers and transferred into reaction 
tubes.  After centrifugation at 2000 rpm for 5 min, cell pellets were resuspended in cell lysis 
buffer and incubated for 20 min on ice. The cell debris was separated from the protein lysate 
by centrifugation at 14,000 rpm for 20 min at 4 °C. The protein lysate was transferred into a 
new reaction tube and either protein concentration was measured or protein lysates were 
frozen. Cell lysates were kept for short-term storage at -20 °C and for long-term storage at -80 
°C. Protein concentrations were assessed by BCA assay according to manufacturer´s 
instructions. Protein lysates with appropriate amount of protein were mixed with 4x SDS-PAGE 
sample buffer to obtain 1x concentration. The samples were boiled either at 70 °C for 
detection of full-length dysferlin or 95 °C for detection of truncated dysferlin and stored at -20 
°C prior to SDS-PAGE. 
 
3.2.2.2. Thrombin and Endo H treatment of HeLa cell culture lysates 
For cleavage of full-length dysferlin, cell lysates with appropriate protein amount were mixed 
with 20 µL of protease thrombin (stock: 100 NIH units/mL in 0.1% BSA/ 50 mM Tris/HCl, pH 
6.8) and incubated for 1 h at 37 °C. Subsequently, removal of N-glycosylation modifications 
was performed by treatment of cell lysates with the endoglycosidase Endo H using the 
supplemented buffers according to manufacturer´s instructions. Shorty, proteins were 
denatured for 10 min at 95 °C prior to Endo H cleavage for 1 h at 37 °C.  
 




3.2.2.3 Isolation of proteins from rat ventricular heart tissue for SDS-PAGE 
Ventricular heart tissue from rats of different age was used for the preparation of protein 
lysates. Therefore, the tissue was weighted and 1.5 mL homogenization buffer per 100 mg 
tissue was added. The cardiac tissue was homogenized 5 times for 5 sec on ice. The 
homogenate was centrifuged two times at 1,300 x g for 10 min at 4 °C and in between 
centrifugation steps the supernatant was transferred into a new reaction tube. The final 
protein lysate was stored at -80 °C or immediately used for the determination of protein 
concentration by BCA assay according to manufacturer´s instructions. SDS-PAGE samples were 
prepared by pooling 10 µg of protein from each rat of the same age and mixing the proteins 
with 4x SDS-PAGE sample buffer to obtain 1x concentration. The samples were boiled at 90 °C 
and stored at -20 °C prior to SDS-PAGE. 
 
3.2.2.4 SDS-PAGE and western blot 
SDS-PAGE was used for the separation of protein samples according to the molecular weight 
of proteins. For efficient separation, a 5% acrylamide stacking gel and, depending on the size 
of proteins to be detected, a resolving gel of 8-15% acrylamide concentration was used. 
Volume of stacking and resolving gel was adjusted to the gel size (small/large gels). 
Subsequently, western blot was performed to determine the protein level of specific proteins. 
The molecular weight of the separated proteins was determined by comparison with a pre-
stained protein ladder. 
 
Table 13 |  Protocol for preparation of stacking and resolving gels for SDS-PAGE 
Component 5% stacking gel 8% resolving gel 15% resolving gel 
Total volume 2 mL 5 mL 5 mL 
Water 1.4 mL 2.3 mL 1.1 mL 
30% acrylamide solution 330 µL 1.3 mL 2.5 mL 
1.0 M Tris, pH 6.8 250 µL / / 
1.5 M Tris, pH 8.8 / 1.3 mL 1.3 mL 
10% SDS 20 µL 50 µL 50 µL 
10% APS 20 µL 50 µL 50 µL 
TEMED 4 µL 6 µL 4 µL 
 




Proteins were concentrated in the stacking gel at 15 mA/25 mA (for small and large gels, 
respectively), followed by separation at 25 mA/45 mA.  
 
Following SDS-PAGE, proteins were electrotransferred to a nitrocellulose membrane. 
Therefore, a sandwich consisting of 3 layers of blotting paper, membrane, gel, 3 layers of 
blotting paper was prepared. The sandwich was placed into the semi-dry blotting system with 
the membrane facing the anode and soaked with transfer buffer. Blotting was performed at 
1.25 mA per cm2 of sanchwich area for 1.5 h. Transferred total proteins were visualized by 
Ponceau-S staining.  
 
For immunostaining the membranes were previously blocked for 1 h with 5% milk, 1% Tween® 
20 in TBS (TBS-T) to avoid unspecific binding of the primary antibody which was incubated o.n. 
at 4 °C. The membranes were washed 3 times for 5 min with TBS-T and incubated with 
horseradish peroxidase (HRP)-coupled secondary antibody diluted in 5% milk/TBS-T for 1h at 
RT. After washing 3 times for 5 min with TBS-T, proteins bound to antibody-complexes were 
visualized by enhanced chemiluminescence (Lumi-Light Western Blotting Substrate) using a 
western blot documentation system LAS-4000. Protein signal was quantified using Fiji 
software. 
 
3.2.3 Molecular biology 
3.2.3.1 Generation of EGFP-DYSF-ops-pcDNA4 
The plasmid containing an ops-tagged DYSF cDNA sequence was generated by the 
amplification of a C-terminal fragment of the DYSF sequence containing the opsin tag 
sequence, which was incorporated into the reverse primer, and cloning of the amplicon into 
the preexisting plasmid EGFP-DYSF-pcDNA4.  
 
3.2.3.2 Generation of EGFP-L1431P-ops-pcDNA4 by DpnI-mediated site-directed 
mutagenesis 
The pathogenic mutation L1341P was introduced into the plasmid EGFP-DYSF-ops-pcDNA4 by 
site-directed mutagenesis and subsequent DpnI digestion. Therefore, KAPA HiFi DNA 
polymerase and primers OST 581 and OST 582 were used. For the mutagenesis reaction, 10 ng 
of template DNA were mixed with 5 µL GC buffer, 0.75 µL of dNTP mix (3.75 mM), 0.75 µL per 




primer (10 µM) and 0.5 µL KAPA HiFi DNA polymerase in a total volume of 25 µL. The reaction 
was performed applying the following program: 
 
 95 °C 3 min 
 98°C 20 sec 
 55 °C 20 sec          25 cycles 
 72 °C 6:30 min  
 72 °C 3 min  
 
Subsequently, the template DNA was removed by digestion of the total reaction mixture with 
1 µL of DpnI for 1:30 h at 37 °C.   
 
3.2.3.3 Amplification of DNA by polymerase chain reaction (PCR) 
The amplification of the C-terminal DYSF fragment and coupling to the opsin tag sequence was 
performed by PCR using PRECISOR High-Fidelity DNA Polymerase. EGFP-DYSF-pcDNA4 was 
used as template. Primers OST587 and pKB17 were used for the amplification. Coupling of 
DYSF to opsin tag was achieved by incorporation of the opsin tag sequence into the reverse 
primer pKB17 and removal of the DYSF stop codon. For the PCR, 10 ng of template DNA were 
mixed with 10 µL of GC buffer, 2.7 µL of dNTP mix (3.75 mM), 1 µL per primer (10 µM) and 1  
µL of polymerase in a total volume of 50 µL. The amplification was performed applying the 
following PCR program: 
 
 98 °C 2 min 
 98°C 30 sec 
 49 °C 30 sec      25 cycles 
 72 °C 1 min 
 72 °C 10 min  
 
3.2.3.4 Restriction of DNA with restriction endonucleases 
DNA fragments and plasmids were cleaved using restriction endonucleases from New England 
BioLabs® Inc. according to manufacturer´s instructions. For cloning of EGFP-DYSF-ops-pcDNA4 
enzymes AfeI and NotI in CutSmart® buffer were used. For test digestion of clones, BamHI-HF® 
in CutSmart® buffer was used. DNA fragment were separated by agarose gel electrophoresis 
and extracted by NucleoSpin® Gel and PCR Clean-up.  
 




3.2.3.5 Ligation of DNA fragments 
For cloning of EGFP-DYSF-ops-pcDNA4 the digested amplicon and plasmid EGFP-DYSF-pcDNA4 
were ligated using T4 DNA Ligase. Ligation was carried out by mixing 50 ng of digested plasmid 
DNA with three-fold molar mass of digested amplicon with 1 μl of T4-ligase and 2 μl 10x ligase 
buffer in a total reaction volume of 20 µL. The ligation mixture was incubated at RT for 30 min 
and subsequently used for transformation of competent E. coli. 
 
3.2.3.6 Transformation of E. coli 
Plasmid DNA was introduced in E. coli bacteria using heat shock. For cloning purposes, 1 µl 
ligation reaction was added to 10 µl of competent E. coli bacterial solution. For transformation 
of mutagenized DNA, 2 µL of mutagenesis mixture was added to 20 µL of competent E. coli 
bacterial solution. Following 20 min of incubation on ice, the transformation mix was set to 
42°C for 70 s. Subsequently, the solution was cooled down on ice for 2 min and 400 µl of LB 
medium were added. After incubation at 37 °C and 300 rpm for 1h, the mixture was plated on 
LB agar plates containing 100 µg/mL ampicillin and cultivated o.n. at 37 °C. Single colonies 
were picked and and small bacterial cultures were prepared by inoculation of 3 mL LB medium 
containing  100 µg/mL ampicillin and o.n. incubation at 37 °C and 200 rpm. 
 
3.2.3.7 Isolation of plasmid DNA from E. coli 
Isolation of plasmid DNA from small E. coli cultures 
Plasmid DNA was isolated from 3 mL o.n. E. coli cultures. Therefore, bacteria were harvested 
at 8000 rpm for 1 min. The pellet was resuspended in 200 μL of buffer P1 and 300 μL buffer of 
P2 was added and the samples were inverted and incubated for 5 min at room temperature. 
300 μL of buffer P3 was added, the samples were inverted and centrifuged for 10 min at 
14,000 rpm. The supernatant was transferred into a new reaction tube and the DNA was 
precipitated with 0.7 volumes of isopropanol and 20 min centrifugation at 14,000 rpm. The 
pellet was washed with 70% ethanol, dried for 10 min at 37 °C and resuspended in 30 μL dH20. 
 
Large bacterial cultures were prepared by inoculation of 100 mL LB medium with 100 µL of 








Isolation of plasmid DNA from large E. coli cultures 
Plasmid DNA was isolated from 100 mL o.n. E. coli cultures. Bacteria were harvested by 20 min 
centrifugation at 3,000 rpm and isolation of DNA was performed according to the 
manufacturer´s instructions using the NucleoSpin® Plasmid kit. DNA was eluted from columns 
with dH2O. 
 
3.2.3.8 DNA sequencing 
For DNA sequencing (Sanger method) the BigDye Terminator v3.1 Cycle Sequencing Kit 
according to manufacturer´s instructions was used. 300 ng of DNA were mixed with 0.5 µL 
sequencing primer (10 µM), 2 µL BigDye 5x buffer and 1 µL BigDye® Terminator v3.1 Ready 
Reaction Mix in a total volume of 10 µL. The reaction was performed as follows: 
 
96 °C 10 sec 
 60°C 4 min, 24 cycles 
 
For purification of the cycle sequencing product 220 μL of 100% ethanol, 120 μL of dH2O and 
10 μL of 3 M sodium acetate (pH 4.6) were added. The mix was vortexed and incubated for 15 
min at RT before centrifugation for 20 min at 14,000 rpm. The pellet was washed with 70% 
ethanol, dried and resuspended in 10 μL formamide. DNA sequencing was performed by 
Andreas Ohlenbusch, department for Child and Adolescent Medicine, University Medical 
Center Göttingen.   
 
3.2.4 Statistics 
Experimental data is presented as mean ±SEM. Statistical analysis was performed using 
Microsoft Excel 2010, GraphPad Prism 4 or SAS® software by student’s t-test assuming normal 
distribution or two-way ANOVA for repeated measurements with Bonferroni’s post hoc 







4.1 Dysferlin and BIN1 localize to different parts of the T-tubule system in 
C2C12 cells 
Previous work of our group demonstrated that dysferlin is able to induce tubular structures 
upon heterologous expression in non-muscle cells and that these induced structures are newly 
formed membrane tubules (Hofhuis et al., 2017). This and other observations such as dysferlin 
binding to PI(4,5)P2 (Hofhuis et al., 2017; Therrien et al., 2009), an abnormally configured T-
tubule system upon dysferlin-deficiency (Klinge et al., 2010a) and localization of dysferlin to 
the developing and regenerating T-tubule system (Klinge et al., 2007, 2010a) lead to the 
hypothesis that dysferlin is involved in membrane remodeling and biogenesis of the T-tubule 
system in skeletal muscle. The BAR domain protein BIN1 may function in a similar fashion. 
BIN1 induces formation of membrane tubules (Lee et al., 2002), a function which is dependent 
on PI(4,5)P2 binding (Fugier et al., 2011), and BIN1-deficiency also leads to muscle disease 
(Nicot et al., 2007). It seems that the tubulation properties of both, BIN1 and dysferlin, 
observed in in vitro and cell experiments, might be the basis for their membrane organizing 
function during myogenic differentiation. To characterize dysferlin and BIN1 during T-tubule 
development, both proteins were immunolabeled in C2C12 cells, a murine myoblast cell line 
which is differentiated into myotubes, and thereby used as model system for muscle 
development and T-tubule biogenesis. As previously reported, endogenous dysferlin and BIN1 
localize to vesicular and tubular structures constituting membranes of the developing T-tubule 
system. Thereby, they partially colocalize especially at the tubular compartment (Klinge et al., 
2007). Confocal microscopy of colabeled C2C12 myotubes reveals that a fairly large amount of 
dysferlin and BIN1 is not colocalizing but is expressed at distinct cellular areas. Dysferlin is 
mainly located at central and perinuclear areas forming a longitudinal tubule network. In 
contrast, BIN1 is rather distal localizing to the sarcolemma and longitudinal membrane 
structures in the proximity of the sarcolemma (Figure 6, A and B). A 3D-volume model of a 
myocyte shows that the inner cell area is mainly composed of dysferlin-labeled membranes 
and the outer area is like a shell which is dominated by BIN1. Furthermore, a layer in between 
the two described areas is characterized by membrane structures at which dysferlin and BIN1 








Figure 6 | Differential localization of dysferlin and BIN1 in developing myotubes.  C2C12 myotubes 
were differentiated for 5 days and co-labeled with antibodies against endogenous dysferlin (green) and 
BIN1 (red). Immunofluorescence samples were visualized by confocal microscopy. (A) Confocal image of 
a single plane of a C2C12 myotube. (B) Single slices of a confocal image stack were combined generating 
an overlay of the myotube (Software Imaris). (C) Confocal image stack was converted into a 3D-volume 
model of the labeled structures (Software Imaris). Scale bars 10 µm. 
 
4.2 Abnormal development of the T-tubule system in LGMD2B patient 
myoblasts 
As previously reported by our group, dysferlin-deficiency does not only lead to a typically 
dystrophic muscle phenotype and an impaired membrane repair (Bansal et al., 2003), but also 
disturbs the T-tubule structure (Klinge et al., 2010a). Labeling of T-tubules from skeletal 





analysis of the muscle tissue reveal irregularity and dilatation of this membrane organelle 
(Klinge et al., 2010a), features that are even enhanced upon notexin-induced muscle 
regeneration (Hofhuis et al., 2017). These results indirectly suggest an important role of 
dysferlin for proper biogenesis of the T-tubule system as they originate from the examination 
of adult mouse muscles. To analyze the effects of dysferlin-loss more directly, myoblasts from 
a LGMD2B patient harboring a splice site mutation in the DYSF gene (c.1939-6T>A) were 
analyzed. Myoblasts can be differentiated in culture, a process during which the cells fuse to 
form multinucleated myotubes and develop a premature T-tubule system. Thereby the cells 
serve as model system for T-tubulogenesis. Human myoblasts were differentiated by serum 
deprivation for 7 days in culture and subsequently analyzed. The homozygous mutation leads 
to a nearly complete loss of dysferlin protein expression as detected by western blot of 
differentiated myoblast lysates (Figure 7, A).  
 
 
Figure 7 | Tubular membrane bundles in LGMD2B patient myotubes.  (A) Dysferlin expression was 
analyzed via western blot using 30 µg whole cell lysate obtained from human control and dysferlin-
deficient (LGMD2B) myotubes after a differentiation time of 7 days. Dysferlin was detected by anti-
dysferlin (NCL-Hamlet) antibody. α-tubulin served as loading control. (B) Representative images of 
human control and dysferlin-deficient (LGMD2B) myotubes after 7 days of differentiation stained with 
the dye DiIC16(3) (12.5 µg/mL in sucrose cacodylate buffer) for 10 min at 37 °C to visualize the 
membrane system. Cells were imaged by confocal microscopy. Arrowheads indicate tubular membrane 
bundles. Scale bars 10 µm. (C) Quantification of cells with tubular membrane bundles as indicated in (B). 
N=3 (15-24 cells/experiment) +/- SEM, ***=P≤0.001 (Student´s t-test). 
 
The membrane system of living cells was stained with the lipophilic red-fluorescent dye 
DiIC16(3) and visualized by confocal microscopy. DiIC16(3) stained the sarcolemma, but also 





control fibers, compact tubular membrane bundles were observed in 36% of dysferlin-
deficient fibers (Figure 7, B and C). These dense formations were located mainly in the 
transverse center and often in the perinuclear region of the myotubes. The compact 
membrane bundles which were observed only in dysferlin-deficient myotubes might be the 
result of an abnormal formation of the T-tubule system due to absence of dysferlin.  
 
4.3 Dysferlin is expressed at the cardiac T-tubule system during 
maturation 
Results showing that dysferlin localizes to the sarcolemma and the T-tubule system (Ampong 
et al., 2005; Anderson et al., 1999; Chase et al., 2009; Klinge et al., 2010a) demonstrate the 
importance of this protein for this organelle in skeletal muscle. Abnormal configuration of the 
adult (Klinge et al., 2010a) and developing (Figure 7) T-tubule system upon dysferlin-deficiency 
gives insight into the pathophysiological mechanisms of muscular dystrophy due to dysferlin 
loss. Dysferlinopathy is mainly described as skeletal muscle disease but there are reports 
suggesting that the heart muscle is also affected by dysferlin-deficiency. Thus, the question 
arises whether dysferlin is not only essential for the biogenesis of the transverse membrane 
system in skeletal muscle but also plays a role in the development of the cardiac T-tubules. To 
answer this question, a time course experiment was performed analyzing dysferlin expression 
in the rat heart at different time points during the first three weeks of life, the time window of 
cardiac T-tubule maturation (Han et al., 2013; Reynolds et al., 2013). Single ventricular 
cardiomyocytes of 11, 14, 17, 20, and 23 days old rats and of adult rats were isolated by 
Langendorff-perfusion (Bell et al., 2011) and endogenous dysferlin as well as CaV1.2 as T-
tubule marker were immunolabeled. The cells were visualized by confocal microscopy. At the 
beginning of the analyzed time period (P11 - P14) cardiomyocytes were comparably small with 
roundish edges. No CaV1.2-labeled structures resembling the T-tubule system were 
detectable, instead CaV1.2 is localizing to the sarcolemma at P14. Over time, cardiomyocytes 
enlarged and developed characteristic sharp edges. CaV1.2 expression increased and localized 
to transverse elements of the maturating T-tubule system. Simultaneously, the dysferlin signal 
showed a similar expression pattern as the T-tubule marker CaV1.2 (Figure 8, A). To quantify 
expression of dysferlin at the T-tubule system, colocalization with CaV1.2 was assessed by 
Mander´s M1 and M2 coefficients (Figure 8, B). Thereby, M1 corresponds to the dysferlin signal 
that is overlapping with CaV1.2 signal normalized to the total dysferlin labeling (M2 vice versa). 





CaV1.2. Over time (P11 - P23), both, M1 and M2 coefficients increase and respective values 
stay similar. Adult cardiomyocytes show the highest M1 and M2 colocalization coefficients of 
0.64 and 0.55, respectively. These values show that the proportion of dysferlin signal 
overlapping with CaV1.2 is higher than the CaV1.2 signal overlapping with dysferlin. To further 
characterize dysferlin expression in developing cardiomyocytes, the protein level was assessed 
by western blot (Figure 8, C). Therefore, hearts were isolated from 11-, 14-, 17-, 20-, 23-day old 
or adult rats and homogenates of the ventricular muscle tissue were prepared. Dysferlin was 
detected by anti-dysferlin (NCL-Hamlet) antibody. GAPDH served as loading control. Western 
blot signal was densitometrically quantified (Figure 8, D) and shows a 7-fold increase in 
dysferlin protein level from P11 to P20. After the peak at P20, dysferlin expression decreases 
again. Analysis of dysferlin in maturating rat cardiomyocytes shows peaked expression at P17 - 






Figure 8 | Dysferlin colocalizes with CaV1.2 in postnatal rat cardiomyocytes and dysferlin expression 
peaks after birth.  P=days after birth. (A) Rat cardiomyocytes were Langendorff-isolated at the indicated 
time points and dysferlin localization was analyzed by confocal microscopy. Representative images of 
rat cardiomyocytes immunolabeled with anti-dyferlin (NCL-Hamlet, green) and anti-CaV1.2 (red) as T-
tubule marker. Scale bars 10 µm. (B) Colocalization of dysferlin and CaV1.2 was analyzed using the 
JACoP plugin of ImageJ and calculating the Manders coefficient. M1=(sum of green pixels colocalizing 
with red)/total green pixels. M2=(sum of red pixels colocalizing with green)/total red pixels. N=1-3 rats 
(5-8 cells/rat) +/- SEM (Student´s t-test). (C) Rat hearts were isolated at the indicated time points and 
ventricular tissue was used for western blot analysis. Dysferlin was deteted by anti-dyferlin (NCL-





Quantification of dysferlin expression based on western blots. Dysferlin level was normalized to GAPDH 
and related to P11. N=3 +/- SEM. 
 
4.4 Dysferlin-deficiency leads to altered transverse-axial tubule system in 
adult cardiomyocytes 
Dysferlin localizes to the developing T-tubule system in rat cardiomyocytes and dysferlin 
expression peaks in a narrow time frame during which maturation of the tubular membrane 
system takes place (Figure 8). Consequently, the effect of dysferlin loss on the morphology of 
this membrane system should be analyzed. Therefore, ventricular cardiomyocytes of control 
(Dysf+/+) and dysferlin-deficient (Dysf-/-) adult mice were Langendorff-isolated (Bell et al., 2011) 
and living cells were stained with the red-fluorescent lipophilic membrane dye di-8-ANEPPS 
(Wagner et al., 2014). Cell integrity criteria such as transverse striation, sharp cell edges and 
lack of membrane blebs were applied to guarantee that only cells that withstood the isolation 
procedure without apparent damage were used for subsequent acquisition of the labeled 
membrane system (Figure 9, top).  
 
 
Figure 9 | Altered morphology of tubular membrane network in ventricular cardiomyocytes of 





) mice by Langendorff-perfusion. The membrane system was stained with di-8-ANEPPS 
for 30 min at RT and cells were imaged by confocal microscopy. Using the software ImageJ, the confocal 
image signal was skeletonized for subsequent detailed analysis of membrane structures. Representative 





The fluorescent signal of the dye was visualized by confocal microscopy (Figure 9, middle). Di-8-
ANEPPS stains the sarcolemma and cytoplasmic membrane structures. The intracellular 
membranes have a predominantly axial (0°) or transverse (90°) orientation. The images of the 
di-8-ANEPPS-labeled transverse-axial membrane system reveal an altered morphology in Dysf-
/--cardiomyocytes compared to dysferlin-competent cells. In order to be able to quantify the 
visually noticeable alterations, the images were skeletonized using an ImageJ plugin (Figure 9).  
 
4.4.1 Dysferlin loss results in reorientated transverse-axial tubule system in 
cardiomyocytes 
The intracellular membrane system in cardiomyocytes has transversely- and axially-orientated 
portions which are both important for a proper cell function (Kirk et al., 2003; Ohler et al., 
2010). Di-8-ANEPPS-staining of adult dysferlin-deficient and control cardiomyocytes reveals 
apparent morphological alterations (Figure 9). The dimension of morphological changes was 
assessed by quantifying the amount of structures for each direction (-45° - 134°) based on the 
skeletonized images of di-8-ANEPPS-labeled cells (Wagner et al., 2014) Figure 9). The 
quantification is depicted as histogram with the amount of structures plotted against the 
structure direction and reveals a bimodal distribution, both, for Dysf+/+ and Dysf-/- 
cardiomyocytes (Figure 10, A). However, the proportion of structures with transverse (90° +/- 
5°) or axial (0° +/- 5°) orientation is significantly changed in dysferlin-deficient cells compared 
to controls (Figure 10, B). Dysferlin-competent cardiomyocytes have 13.4% axially and 16.0% 
transversely orientated structures. In dysferlin-deficient cells the distribution is changed to 
20.1% and 8.8% axial and transverse orientation, respectively (Figure 10, C). Thus, dysferlin-







Figure 10 | Altered directionality of transverse-axial tubule system in ventricular cardiomyocytes of 





) cardiomyocytes (Figure 9) were used for quantification of structure directionality 














 bars next to each other. Gray boxes mark area of direction with 




 for each bin (16° to 24°, 64° to 118°. *=P≤0.05 (Two-
way ANOVA with repeated measures). (C) Summed amount of structures with axial (0° +/- 5°) and 





4.4.2 Structural parameters of skeletonized tubular membranes are changed 
in dysferlin-deficient cardiomyocytes 
To characterize the membrane system of dysferlin-deficient compared to control 
cardiomyocytes more detailed, structural parameters such as skeleton length, number of 
structures, number of branches and number of end-point voxels were measured on the basis 
of the skeletonized di-8-ANEPPS images and normalized to the cell area (Wagner et al., 2014). 
Furthermore, the average branch length was assessed. The cell area was unchanged. The same 
is true for the average branch length. Though, the number of structures and the number of 
branches were decreased, thereby reducing the total skeleton length and the number of end-
point voxels. Thus, dysferlin-deficiency leads to a reorganization of the membrane system with 
redirection and reduction of tubular structures (Figure 11).  
 
Figure 11 | Altered structural parameters of transverse-axial tubule system in ventricular 
cardiomyocytes of dysferlin-deficient mice.  Skeletonized images of di-8-ANEPPS-stained dysferlin-
competent (Dysf
+/+
) and -deficient (Dysf
-/-
) cardiomyocytes (Figure 9) were analyzed with the Analyze 
Skeleton (2D/3D) plugin of ImageJ. The following parameters were used to characterize the skeletonized 
transverse-axial tubule system: Cell area, normalized skeleton length, normalized number of structures, 
normalized number of branches, average branch length, normalized number of end-point voxels. 
Skeleton length, number of structures, number of branches and number of end-point voxels were 




) mice, (5-20 cells/mouse) +/- SEM. **=P≤0.01, 






4.5 Dysferlin gets inserted into the ER  
To understand the pathomechanisms underlying dysferlin-deficient muscular dystrophy and to 
find therapeutic intervention targets it is important to know the route of dysferlin through the 
cell. Until now, little is known about the fate of the protein after its synthesis. Because of its 
single C-terminal transmembrane domain dysferlin is counted to the TA proteins, which are 
inserted into the ER membrane directly after their cytosolic translation. Integration of a 
protein into the ER can be analyzed by coupling the protein of interest to an opsin tag 
harboring an N-glycosylation site and detection by western blot. The modification occurring in 
the lumen of the ER leads to a mobility shift of the protein during electrophoresis of up to 3 




Figure 12 | Use of the glycosylation tag opsin as reporter for protein integration into the ER.  (A) 
Amino acid sequence of the short variant of the glycosylation tag opsin, derived from the bovine 
rhodopsin, contains one glycosylation site (respective amino acids marked in bold letters, asparagine (N) 
which can be glycosylated indicated by a fork). (B) Schematic representation of the glycosylation of an 
opsin-tagged protein inside the ER lumen upon protein integration into the ER. (C) C-terminally opsin-
tagged full-length dysferlin (Dysferlin-ops) used for expression in mammalian cells. 
 
Though, dysferlin is a protein of 230 kDa making it unfeasible to detect glycosylation when 
separating the full-length protein by SDS-PAGE. To overcome this obstacle, we aimed to cleave 
dysferlin and analyze a considerably smaller peptide with respect to glycosylation. The tool 
PeptideCutter (http://web.expasy.org/peptide_cutter/) of the bioinformatics resource portal 





enzyme thrombin was found to have two recognition sites within the dysferlin protein 
sequence at positions 187 aa and 1806 aa (Figure 13, A).  To test, whether the cleavage of 
dysferlin by thrombin was specific and effective and whether dysferlin gets integrated into the 
ER membrane, HeLa cells were transfected with constructs encoding untagged or opsin-tagged 
full-length dysferlin (Dysferlin and dysferlin-ops, respectively). Cell lysates were either 
nontreated or digested with thrombin and analyzed by SDS-PAGE and western blot (Figure 13, 
B). Untagged dysferlin was detected by anti-dysferlin NCL-Hamlet antibody which recognizes 
an epitope at 1999 - 2016 aa of the dysferlin protein and dysferlin-ops was detected by anti-
opsin antibody (Scheme of antibody recognition sites in Figure 13, A). The anti-opsin antibody 
recognizes a protein at 35 kDa independently of cell type, transfected construct (also 
untransfected control) or treatment of cells or cell lysates. Therefore, this prominent band is 
considered as unspecific for the antibody. Full-length dysferlin is detected in all samples at the 
top of the blot (above the 170 kDa marking). Cleavage of uncoupled dysferlin by thrombin 
leads to a reduction of full-length dysferlin and to an additional protein band which is detected 
at approximately 33 kDa. This band represents the C-terminal dysferlin fragment including the 
C2G and transmembrane domain. Digestion of dysferlin-ops by thrombin also results in the 
generation of smaller peptides. The two bands that are detected just above the 35 kDa 
marking also represent the C-terminal fragment of dysferlin. In comparison to the untagged 
version, they have a reduced electrophoretic mobility due to the opsin tag and therefore are 
visible at a higher position on the blot. In contrast to uncoupled dysferlin, two well separated 
bands are detected for dysferlin-ops which might represent a nonglycosylated (lower band) 
and glycosylated (upper band) peptide. Thus, this result indicates that full-length dysferlin gets 
inserted into the ER in HeLa cells and thrombin cleavage is a feasible way to make 






Figure 13 | Site-specific Thrombin cleavage of dysferlin as prerequesite for glycosylation analysis.  (A) 
Thrombin cleavage of full-length opsin-tagged dysferlin at the positions aa 187 and aa 1806 results in a 
C-terminal peptide of approximately 30 kDa which can be detected either by anti-dysferlin (NCL-Hamlet) 
or anti-opsin antibody. (B) HeLa cells were transfected with dysferlin or dysferlin-ops and harvested 48 
h post transfection for western blot analysis. Protein samples of 20 µg were either nontreated or 
digested with thrombin for 1 h at 37°C and loaded on SDS-PAGE. Dysferlin was detected by anti-
dysferlin (NCL-Hamlet) antibody and dysferlin-ops by anti-opsin antibody. Arrowheads indicate cleaved 
C-terminal part of dysferlin (left blot) or dysferlin-ops (right blot). 
 
4.5.1 Efficiency of dysferlin insertion into the ER varies between mammalian 
cell lines  
Analysis of opsin-tagged dysferlin expressed in HeLa cells and cleaved with thrombin shows 
that two bands can be detected by western blot (Figure 13, B). To verify that the upper band 
represents an N-glycosylated form of the lower one, the thrombin digested lysate was 
additionally treated with the endoglycosidase Endo H which removes N-linked oligosaccharide 
modifications (Roth et al., 2012). Western blot of Endo H-treated samples shows the 
disappearance of the upper band and increased level of the lower band compared to the 
untreated sample (Figure 14, A) confirming that the electrophoretic mobility shift is due to 
glycosylation and that dysferlin is C-terminally inserted into the membrane of the ER in HeLa 
cells. To answer the question whether dysferlin insertion into the ER is specific for HeLa cells, 
dysferlin-ops glycosylation was analyzed in the mammalian cell lines HEK293, COS-7 and CHO-
K1. A glycosylated form of dysferlin can be detected in all tested cell lines (Figure 14, A). 
However, the level of glycosylated protein compared to the nonglycosylated is not equal. 
Thus, the proportion of glycosylated dysferlin was calculated by the ratio of glycosylated to 





glycosylation and therewith the integration of dysferlin into the ER differs between cell lines. 
HeLa cells have the lowest insertion efficiency with 56% of dysferlin being glycosylated. 
Glycosylation is significantly higher in COS-7 and CHO-K1 cells with a proportion of 77% and 
89%, respectively. Glycosylation in HEK293 cells also tends to be higher compared to HeLa 
cells, but the difference is not significant. The trafficking of dysferlin is of particular interest in 
muscle cells as mutations in the DYSF gene lead to alterations in protein transport and stability 
causing muscular dystrophy. Therefore, glycosylation of dysferlin-ops was analyzed in the 
myoblast cell line C2C12. Also in these immature skeletal muscle fibers dysferlin is inserted 
into the membrane of the ER as shown by western blot (Figure 14, C). Quantification reveals 
that approximately 80% of dysferlin are glycosylated (Figure 14, D). Thus, using the opsin tag as 
glycosylation sensor it could be shown that dysferlin is being integrated into the ER with its C-
terminus facing the lumen in different cell lines including a muscle cell line and that the 
efficiency of ER insertion varies in these cell systems.  
 
 
Figure 14 | Differential glycosylation of dysferlin-ops in mammalian cell lines. Glycosylation of 
dysferlin-opsin in mammalian cells was analyzed via western blot using an anti-opsin antibody. Bands 
representing glycosylated and nonglycosylated dysferlin-ops are indicated. (A) Non-muscle cell lines 
HeLa, HEK293, COS-7 and CHO-K1 were transfected dysferlin tagged to the glycosylation sensor opsin 
(dysferlin-ops) and harvested 48 h post transfection. Cell lysates of 30 µg protein were thrombin-
digested for 1 h at 37 °C and either nontreated or treated with Endo H for 1 h at 37 °C. (B) Western blots 
were analyzed using the software Fiji to calculate the ratio of glycosylated dysferlin-ops relative to total 
level. N≥4 +/- SEM, *=P≤0.05, **=P≤0.01 (Student´s t-test). (C) C2C12 myoblasts were transfected with 
dysferlin-ops and harvested 72 h post transfection. Cell lysates of 65 µg protein were thrombin-digested 
for 1 h at 37 °C and either nontreated further or treated with Endo H for 1 h at 37 °C. (D) The ratio of 






4.5.2 Increased glycosylation of dysferlin mutant L1341P compared to wild-
type in HeLa cells  
LGMD2B and MM are often caused by missense mutations in the DYSF gene. The substitution 
of a single amino acid in the 2080 aa protein can be sufficient to cause structural changes, 
mislocalization, instability and degradation, ultimately resulting in loss of functional dysferlin. 
In this study two missense mutations were characterized which are often found in 
dysferlinopathy patients: mutation c.2875C>T causes the substitution of arginine to 
tryptophan at protein position 959 in the C2D domain of the protein (R959W) and c.4022T>C 
causing the substitution of leucine to proline at protein position 1341 which is in the C2E 
domain (L1341P) ((Klinge et al., 2010b; Wenzel et al., 2006)). It has been reported that L1341P 
is prone to aggregation in the ER and autophagic degradation (Fujita et al., 2007).  
 
 
Figure 15 | Protein domain diagram of dysferlin variants.  C2 domains are depicted in green (C2), the 
transmembrane domain is depicted in brown (TM), ferlin domains are depicted in blue. The wild-type 
dysferlin (WT dysferlin) at the top row. Missense mutations R959W and L1341P are indicated by red 
stars at the respective protein position. 
 
To analyze whether the insertion of mutant L1341P into the ER membrane is altered in 
comparison to wild-type dysferlin, HeLa cells were transfected with constructs encoding one 
or the other dysferlin variant tagged to the glycosylation sensor opsin. Cell lysates were 
treated with thrombin to obtain a shorter peptide and subsequently either nondigested or 
digested with the endoglycosidase Endo H. Glycosylation was visualized by western blot (Figure 
16, A) and proportion of glycosylated protein was calculated by the ratio of glycosylated to 
total protein level (Figure 16, B). This experiment reveals that the proportion of glycosylated 
protein is about 1.5-fold higher for the dysferlin mutant L1341P compared to wild-type 
dysferlin indicating that insertion into the ER is more efficient. Additionally, the total protein 






Figure 16 | Increased glycosylation of mutant L1341P compared to wild-type in HeLa cells.  
Glycosylation of opsin-tagged dysferlin wild-type and mutant dysferlin was analyzed via western blot. 
(A) HeLa cells were transfected with constructs encoding either dysferlin wild-type (Dysferlin-ops) or 
mutant L1341 (L1341-ops) coupled to the glycosylation sensor opsin and harvested 48 h post 
transfection. Cell lysates of 30 µg protein were thrombin-digested for 1 h at 37 °C and either nontreated 
further or treated with EndoH for 1 h at 37 °C to remove glycosylation modifications. A representative 
western blot is depicted. (B) Western blots were analyzed using the software Fiji to calculate the ratio of 
glycosylated relative to total dysferlin-ops and L1341P levels. N3 +/- SEM, *=P≤0.05 (Student´s t-test). 
 
4.6 Depletion of the TRC40 pathway component WRB has no effect on 
the localization or steady-state level of dysferlin 
TA proteins have a single transmembrane domain at the very C-terminus causing the 
requirement of a special post-translational membrane insertion mechanism. One targeting 
pathway depending on the cytosolic ATPase TRC40 and its ER membrane-located receptor 
complex consisting of WRB and CAML was found to post-translationally insert a number of 
tail-anchored proteins into the ER (Favaloro et al., 2008; Pfaff et al., 2016; Stefanovic and 
Hegde, 2007). The mechanism of ER insertion highly depends on the hydrophobicity of the 
transmembrane domain. TA proteins with transmembrane domains of high hydrophobicity are 
preferentially inserted by the TRC40-dependent pathway (Rabu et al., 2008; Stefanovic and 
Hegde, 2007). On the route to its target membrane the TA protein dysferlin is also inserted 
into the membrane of the ER (Figure 13-Figure 15) and the transmembrane domain has a 
comparably high hydrophobicity of 70.6 (According to hydropathy scale of (Kyte and Doolittle, 
1982). Furthermore, dysferlin is highly expressed at the T-tubule system of developing 
cardiomyocytes (Figure 8). Thus, the effect of TRC40 pathway loss on the expression and 
localization of dysferlin in ventricular cardiomyocytes was investigated in cooperation with Dr. 
Jhon Rivera-Monroy and Prof. Blanche Schwappach from the department of Molecular 
Biology, University Medical Center Göttingen. Cardiomyocytes were isolated by Langendorff-
perfusion (Bell et al., 2011), performed by Dr. Jhon Rivera-Monroy) from cardiomyocyte-





immunofluorescence was performed (Rivera-Monroy et al., 2016). Dysferlin was expressed in 
both, WRB-knockout and control cells and showed striated expression pattern indicating T-
tubule localization as well as localization to intercalated discs (Figure 17, A). Dysferlin 
expression level was analyzed on the basis of confocal immunofluorescence images and 
calculated as corrected total cell fluorescence (CTCF) by subtracting the background multiplied 
with the cell area from the integrated cell intensity. No change in dysferlin CTCF was observed 
for WRB-knockout compared to control cardiomyocytes (Figure 17, B). Additionally, dysferlin 
steady-state level was assessed by western blot of heart homogenates from cardiomyocyte-
specific WRB-deleted mice and densitometric evaluation (Figure 17, C, performed by Dr. Jhon 
Rivera-Monroy). There was no altered dysferlin steady-state level upon WRB-knockout (Figure 
17, D). Dysferlin is a TA protein with a strongly hydrophobic domain. However, knockout of the 
TRC40 insertion pathway does not lead to an effect on dysferlin expression or localization in 
ventricular cardiomyocytes.  
 
Figure 17 | No effect of cardiac Wrb knockout on dysferlin localization and expression. Mouse 
ventricular cardiomyocytes were isolated from 8 week-old MerCreMer - (Cre-) and MerCreMer + (Cre-, 
knockout) Wrb
fl/fl
 littermates after tamoxifen induction (Performed by Dr. Jhon Rivera-Monroy). (A) 
Localization and expression of dysferlin was analyzed by indirect immunofluorescence and confocal 
microscopy (LSM 710). Representative confocal immunofluorescence images are depicted. Scale bars 10 
µm. (B) Quantification of dysferlin expression on the basis of confocal immunofluorescence images. 
Calculated as corrected total cell fluorescence (CTCF) by subtracting the background multiplied with the 
cell area from the integrated cell intensity. N= 3 mice per genotype (5 cells/mouse). Mean +/- SEM. (C) 
Dysferlin steady-state level was assessed by western blot using anti-dysferlin antibody. Anti- GAPDH and 
Anti-sodium potassium ATPase (NaK ATPase) served as loading control. Anti-WRB antibody was used to 
confirm downregulation of WRB. (D) Densitometric quantification of dysferlin steady-state protein level 






4.7 PBA increases steady-state level of dysferlin variants 
In this study two mutations were characterized with regard to protein level and a possibility to 
stabilize the proteins. This would provide information about the pathomechanism of 
dysferlinopathy and possible targets for the treatment of this disease. Dysferlin variants 
harboring the two missense mutations R959W and L1341P, located in the C2D and C2E 
domain, respectively, were analyzed (Figure 15). Initially, the expression levels were 
investigated. HeLa cells were transfected with constructs encoding either wild-type dysferlin 
or one of the mutant variants and cell lysates were analyzed by western blot. Both mutants 
show reduced steady-state levels compared to wild-type dysferlin (Figure 18). It has been 
reported that R959W leads to structural changes in the dysferlin protein (Espinoza-Fonseca, 
2016) and L1341P is prone to aggregation in the ER and autophagic degradation (Fujita et al., 
2007). This might explain the reduced steady-state levels of mutated dysferlin. Small 
molecules, which have the ability to shield hydrophobic regions of misfolded proteins and 
thereby reduce protein aggregation, may be called hydrophobic chaperones (Cortez and Sim, 
2014). The short chain aromatic fatty acid 4-phenylbutyrate (PBA) is converted in vivo into 
phenylacetate by β-oxidation and this metabolic intermediate is degraded by conjugation to 
the amino acid glutamine and eliminated via the urinary system (Brusilow, 1991). Due to is 
metabolic pathway, PBA functions as an “ammonia scavenger” (Iannitti and Palmieri, 2011) 
and is therefore approved by the FDA for the clinical treatment of children with urea cycle 
disorders (https://www.fda.gov/default.htm). Additionally, PBA acts as histone deacetylase 
inhibitor and protein chaperone. It modulates cellular gene expression and reduces ER stress 
as well as the unfolded protein response leading to reduced ER-stress induced apoptosis 
(Iannitti and Palmieri, 2011). Due to is versatile functions, PBA is currently under investigation 
for the treatment of several disorders, such as cystic fibrosis (Lim et al., 2004; Rubenstein et 
al., 1997), neurogenerative diseases like Alzheimer´s disease (Bondulich et al., 2016; 
Cuadrado-Tejedor et al., 2011), myocardial ischemia (Takatori et al., 2017), cancer (Carducci et 
al., 2001) and many others (Braun and Schweizer, 2017; Cao et al., 2016; Collins et al., 1995; 
Khan et al., 2017; Liu et al., 2016).  
PBA is a regulator of cellular proteostasis and was therefore used in this study to test whether 
it is a suitable therapeutic for the treatment of dysferlinopathy by ameliorating the reduced 
protein level of dysferlin mutants. Transfected HeLa cells were treated with PBA for 24 h and 
cell lysates were analyzed by western blot. PBA treatment leads to a significant increase of 
steady-state level for wild-type and R959W. Also, the protein level of mutant L1341P tends to 





treatment is 1.5-fold of the wild-type level without PBA. Thus, PBA has the potency to increase 
reduced steady-state levels of dysferlin mutants and also the level of wild-type dysferlin.  
 
 
Figure 18 | Increased steady-state level of dysferlin WT and mutants R959W and L1341P upon PBA 
treatment.  (A) Representative immunoblots of lysates from HeLa cells transfected with dysferlin wild-
type or missense mutants R959W and L1341P and either nontreated or treated with the chemical 
chaperone PBA at 5 mM for 24 h. Dysferlin was deteted by anti-dyferlin (NCL-Hamlet), anti-α-tubulin 
served as loading control. (B) Densitometric quantification of western blot. Dysferlin level was 
normalized to α-tubulin. N=3-8. Mean +/- SEM. *=P≤0.05, **=P≤0.01 (Student´s t-test). 
 
4.8 No effect of PBA on tubulation properties of wild-type dysferlin in 
HeLa cells 
Heterologous expression of wild-type dysferlin in non-muscle cells leads to the generation of 
membrane tubules which were shown to have similarities to T-tubules of muscle cell with 
regard to structure and lipid composition (Hofhuis et al., 2017). Previous work of our group 
suggests that the ability of dysferlin to form membrane tubules is a central function of the 
protein during development and maintenance of the T-tubule system. As previously reported 
by our group, wild-type dysferlin expressed in non-muscle cells does neither colocalize with 
the Golgi apparatus, nor with the ER (Hofhuis et al., 2017) as shown by immunostaining of 
EGFP-dysferlin transfected cells for giantin and PDI as Golgi and ER marker, respectively (Figure 
19, A and B, top). To analyze whether the increased steady-state level upon PBA treatment 
leads to a distinct localization of dysferlin, transfected cells were incubated with PBA for 24 h 
and subsequently used for indirect immunofluorescence. No change in expression or 
localization of wild-type dysferlin is detectable by epifluorescence microscopy of dysferlin-






Figure 19 | Wild-type dysferlin does neither colocalize with Golgi marker giantin, nor with ER marker 
PDI.  Representative immunofluorescence images of HeLa cells transfected with EGFP-tagged wild-type 
dysferlin (EGFP-DYSF) and either nontreated or treated with the chemical chaperone PBA at 5 mM for 
24 h. (A) The Golgi network was immunolabed with an antibody against giantin (red). (B) The ER was 
immunolabed with an antibody against PDI (red). Nuclei are stained with DAPI (blue). Cells were 
analyzed by epifluorescence microscopy and z-stacks were deconvoluted. Scale bars 10 µm. 
 
PBA ameliorates the tubulation deficiency of dysferlin mutant R959W, but has no effect on 
L1341P in HeLa cells 
When assuming that deformation of membranes into tubular structures is the main function 
of dysferlin in muscle cells, the tubulation property of dysferlin variants in non-muscle cells 
can be used as read-out for proper dysferlin function. Localization to cellular organelles and 





contrast to wild-type dysferlin, heterologous expression of R959W does not lead to the de 
novo synthesis of tubular membranes (Figure 20, A and B, top). R959W does not localize with 
ER marker PDI (Figure 20, B, top) but shows strong overlap with Golgi marker giantin (Figure 20, 
A, top). More detailed comparison of R959W- and giantin-labeled structures reveals that they 
do not completely overlap, but are rather strongly associated with each other. Assuming that a 
certain minimal protein level of full-length dysferlin is necessary for its tubulation function, the 
absence of R959W-induced membrane tubules might be explained by its reduced steady-state 
level due to protein instability caused by the amino acid substitution (Figure 18). Thus, the 
effect of PBA on localization of mutant R959W was investigated to analyze whether the 
increased protein level correlates with tubulation. PBA treatment leads to the generation 
R959W-labeled membrane tubules as reported for wild-type dysferlin in a proportion of 
transfected HeLa cells. The tubular structures do neither colocalizes with the Golgi apparatus, 
nor with the ER (Figure 20). 
The dysferlin mutant L1341P also has no tubulation ability in untreated HeLa cells (Figure 21, A 
and B, top). The mutated protein localizes to the ER as shown by strong overlap with the PDI 
signal (Figure 21, B, top) and reported previously (Fujita et al., 2007). Colocalization with the 
Golgi apparatus is not detectable by epifluorescence microscopy (Figure 21, A, top). Treatment 
of L1341P-transfected HeLa cells had no effect on the expression or localization of the mutant 
in immunofluorescence and did not lead to induced membrane tubulation (Figure 21, A and B, 
bottom).  
Heterologous expression of dysferlin mutants R959W and L1341P shows that none of the 
mutants have tubulation properties, but rather associate with the cellular organelles Golgi and 
ER, respectively. PBA ameliorates the tubulation deficiency of Golgi-associated R959W, but not 






Figure 20 | Dysferlin mutant R959W colocalizes with giantin and PBA rescues tubulation deficiency of 
R959W mutant.  Representative immunofluorescence images of HeLa cells transfected with the EGFP-
tagged dysferlin missense mutant R959W (EGFP-R959W) and either nontreated or treated with the 
chemical chaperone PBA at 5 mM for 24 h. (A) The Golgi network was immunolabed with an antibody 
against giantin (red). (B) The ER was immunolabed with an antibody against PDI (red). Nuclei are stained 
with DAPI (blue). Cells were analyzed by epifluorescence microscopy and z-stacks were deconvoluted. 







Figure 21 | Dysferlin mutant L1341P partially colocalizes with the ER marker PDI.  Representative 
immunofluorescence images of HeLa cells transfected with the EGFP-tagged dysferlin missense mutant 
L1341P (EGFP-L1341P) and either nontreated or treated with the chemical chaperone PBA at 5 mM for 
24 h. (A) The Golgi network was immunolabed with an antibody against giantin (red). (B) The ER was 
immunolabed with an antibody against PDI (red). Nuclei are stained with DAPI (blue). Cells were 






4.9 Dysferlin mutant R959W closely associates with the Golgi marker 
giantin in C2C12 myoblasts 
To get further insight into the pathomechanism of dysferlinopathy caused by missense 
mutations, the localization of dysferlin mutant R959W was investigated in differentiated 
C2C12 myoblasts, a model system for T-tubule development in skeletal muscle cells. 
Therefore, C2C12 myoblasts were transfected with either EGFP-tagged wild-type or mutant 
dysferlin and differentiated for 5 days in culture. Differentiated myotubes were used for 
indirect immunofluorescence to label the Golgi by staining the marker giantin. As previously 
reported, wild-type dysferlin labels predominantly tubular structures with longitudinal 
orientation, representing the maturating T-tubule system (Hofhuis et al., 2017). EGFP-dysferlin 
does not show overlap with the giantin signal but in several regions of the cells dysferlin-
labeled tubules are in close contact and seem to entangle giantin-labeled Golgi sheets (Figure 
22, A). Heterologously expressed dysferlin mutant R959W does not localize to the longitudinal 
membrane structures of the developing T-tubule system. Like in HeLa cells, R959W shows 
partial overlap with giantin-labeled portions of the Golgi apparatus (Figure 21, B). As the 
overlap is not complete, this speaks rather for a close association of R959W- and giantin-






Figure 22 | While wild-type dysferlin localizes to the T-tubule system, mutant R959W closely 





transfected with either EGFP-tagged wild-type dysferlin (EGFP-DYSF, (A)) or the missense mutant 
R959W (EGFP-R959W, (B)). The Golgi network was immunolabed with an antibody against giantin (red). 
Nuclei are stained with DAPI (blue). Cells were analyzed by epifluorescence microscopy and z-stacks 
were deconvoluted. Scale bars 10 µm. 
 
 
4.10 Readthrough of DYSF patient nonsense codons can be differentially 
induced by G418  
Dysferlinopathy is caused by mutations in the DYSF gene. 80 different mutations are known in 
at least three unrelated patients (UMD-DYSF mutations database, 
http://www.umd.be/DYSF/W_DYSF/mutation.html). In 25% of the patients disease is caused 
by mutations leading to the generation of a stop codon and consequently to premature 
termination of translation (Figure 23).  
 
 
Figure 23 | Spectrum of nonsense mutations in the DYSF gene.  Figure shows the positions of all known 
mutations leading to the generation of a premature stop codon (nonsense mutation) in the human DYSF 
gene in at least three unrelated index patients (information extracted from UMD-DYSF mutations 
database, http://www.umd.be/DYSF/W_DYSF/mutation.html) and the affected amino acids of the 
dysferlin protein. 
 
One therapeutic approach for the treatment of genetic diseases caused by premature stop 
codons is the application of aminoglycosides, their derivatives or other small molecules which 
are able to induce translational readthrough of premature stop codons leading to production 
of the full-length protein. Gentamicin and G418 are aminoglycosides investigated as 
readthrough inducers, e.g. for the treatment of Duchenne muscular dystrophy (Barton-Davis 
et al., 1999; Loufrani et al., 2004). However, these substances have a narrow therapeutic 
window and they are nephro- and ototoxic. Therefore, the application of these 
aminoglycosides should be carefully evaluated. The therapeutic efficacy varies strongly from 
patient to patient and currently no prediction about whether and to which extent readthrough 
will be induced can be made prior to treatment. Our group has established a very sensitive 





and downstream) by flow cytometric analysis of cells transfected with a SCC-encoding 
construct (Hofhuis et al., 2017b).  
 
 
Figure 24 | Schematic representation of dual reporter for readthrough analysis in mammalian cells.  A 
construct consisting of the stop codon (violet) of interest and its adjacent nucleotides (Stop codon 
context, SCC) surrounded by genes encoding TagRFP and EGFP up- and downstream of the SCC, 
respectively is transfected into mammalian cells. Following flow cytometric acquisition of the 
fluorescent signal, the extent of readthrough at the respective stop codon is calculated as EGFP over 
TagRFP fluorescence ratio. 
 
Readthrough extent is influenced only by the stop codon itself (UGA having the highest 
readthrough propensity) and the nucleotides surrounding the stop codon (Schueren et al., 
2014; Tate et al., 1996). The dual reporter assay was used to investigate the basal (without 
induction) and G418-induced readthrough of the 18 known nonsense codons in the DYSF 
gene. Therefore, the SCCs (Table 14) were cloned into a mammalian expression construct with 
an N-terminal TagRFP sequence as internal expression control and a C-terminal EGFP 
sequence as readthrough sensor (Performed by Corinna Dickel and Marco Schmidt). HeLa cells 
were transfected and subsequently either nontreated or incubated with G418 for 18 h. Cells 
were analyzed 24 h after transfection by two channel fluorescence flow cytometry for the 
expression of TagRFP and EGFP. Readthrough was calculated as green over red fluorescence 
ratio and normalized to a 100% readthrough control (no stop codon between TagRFP and 
EGFP coding sequences).  
 
Table 14 |  DYSF nonsense mutations 
Amino acid position cDNA position SCC 
R89X 265C>T G GTC CCA CTC TGA GAG GTC CTC G 
Q111X 331C>T C ACC AAG AAG TAG CCC ACA GGG G 
R204X 610C>T C AAA AGA AAG TGA AGT GCG CCT A 
Q231X 691C>T C GAG GGG CGC TAG CTG CCG GGG G 
Y522X 1566C>G T GGG CCC TGC TAG ATC AAC CTC T 





Y586X 1758C>T G GTG GAG AAG TAG CTT AGG AGG C 
E605X 1813C>T C ACC ATG CTG TAG GAT GTG GAT G 
E612X 1834C>T T GAT GCC ATC TAG TTT GAG GTC A 
E832X 2494C>T T GGG AAG CTA TAG ACA ATC TTT C 
R1038X 3112C>T C TAC ACA CAC TGA CGG CGG CGC T 
S1173X 3516_3517delTT A CTC TTT TTC TGA TCC CTA TGC C 
Q1269X 3805G>T G CCG TCG GGG TAG CTG CTG GCC T 
E1278X 3832C>T T GAG CTC ATC TAG AGA GAG AAG C 
C1398X 4194C>A G GAG CTC TAC TGA CCC CCC ATC A 
R1586X 4756C>T C TAC ATT GTC TGA GCA TTT GGC C 
R1905X 5713C>T A ATC CCA GCA TGA GTG GTG TTC C 
W1968X 5903G>A A GTG AAG GGC TGA TGG CCC TGT G 
 
The basal translational readthrough of DYSF nonsense SCCs is less than 1%, ranging from 
0.29% (R204X) to 0.87% (E1278X) (Figure 25). Treatment with G418 leads to significant 
readthrough induction for all tested SCCs. Readthrough of induced SCCs ranges from 1.46% 
(E832X) to 10.40% (W1968X), thus, readthrough level differs by up to 7-fold. The readthrough 
level upon induction does not correlate with the basal level. If the readthrough level is 
equivalent to the proportion of translated full-length protein, the results suggest that without 
induction less than 1% of protein is produced but induction with G418 increases amount of 






Figure 25 | Differential readthrough induction efficiancy of DYSF SCCs by G418.  HeLa cells were 
transfection with the dual fluorescence reporter construct encoding SCCs of the known nonsense 
mutations in the human DYSF gene or a construct with no stop codon between the fluorescence tags 
(100% readthrough control) (cloned by Corinna Dickel and Marco Schmidt). 6 h after transfection, cells 
were either nontreated or treated with G418 (100 µg/mL) for another 18 h. Reporter fluorescence was 
analyzed 24 h post transfection by flow cytometry. Following gating according to FSC/SSC and green/red 
fluorescence, readthrough was calculated as EGFP over TagRFP fluorescence ratio normalized to the 







Dysferlin is a protein which is mainly expressed in skeletal and heart muscle. For a long time, it 
has mainly been implicated in membrane repair (Bansal and Campbell, 2004; Cai et al., 2009; 
Lek et al., 2013). In recent years, accumulating evidence uncovered an additional and 
fundamental role for dysferlin. Dysferlin leads to the generation of elongated membranes 
upon heterologous expression in non-muscle cells or incubation with liposomes. These tubules 
are characterized by biochemical and morphological similarities with the muscular tubule 
system leading to the hypothesis that the tubulation capacity of dysferlin mirrors the primary 
cellular function of the protein, namely the formation of the T-tubule system in skeletal 
muscle (Hofhuis et al., 2017). 
 
5.1 Dysferlin and BIN1 function at different subcompartments of the 
tubule system during development 
The BAR domain protein BIN1 is an established key player during biogenesis of the tubule 
system (Hong et al., 2014, 2010; Lee et al., 2002). It is found early at the membrane of the 
developing tubule system and regulates recruitment and clustering of EC coupling proteins L-
type Ca2+ channel and RyR at the functional units of the muscle cells (Fu et al., 2016; Hong et 
al., 2014, 2010; Lee et al., 2002). One of BIN1´s molecular functions was determined by 
heterologous expression in non-muscle cells and incubation of recombinant BIN1 with 
liposomes (Lee et al., 2002). In these systems, the generation of membrane tubules was 
observed. The tubules are analogous to those observed in dysferlin-induced tubulation with 
partial colocalization when expressed in one system. Still, also differences comparing BIN1- 
and dysferlin-induced tubules were observed. BIN1-induced tubules are longer and more 
branched then those induced by dysferlin. In contrast to BIN1, dysferlin induces membrane 
tubulation in a dynamin 2-independent manner. These differences indicate that the 
mechanism underlying membrane tubulation differs between BIN1 and dysferlin (Hofhuis et 
al., 2017). To follow up on the difference between those two T-tubule proteins, their 
endogenous localization was studied in C2C12 myotubes in the frame of this study. In culture 
differentiated C2C12 cells resemble differentiation of skeletal myofibers and biogenesis of the 
T-tubule system. Dysferlin and BIN1 show partial colocalization in this system. Though, BIN1 
and dysferlin also label different structures with dysferlin localizing to central tubules and BIN1 
labeling tubules in proximity to the plasma membrane. Thus, dysferlin and BIN1 localize to 





distinct specialized roles for the formation of the tubule system. During embryonic 
development and initial phases of tubule biogenesis, CaV1.1, the L-type Ca
2+ channel in skeletal 
muscles, is localized at the sarcolemma before translocating to the tubule membrane in later 
stages (Romey et al., 1989). BIN1 is strongly associated with the L-type Ca2+ channel during 
development. In cardiomyocytes, BIN1 recruits CaV1.2 molecules, which are transported on 
polymerizing microtubules, arising from the Golgi, to the membrane of the tubule system and 
clusters them compactly in membrane microdomains (Hong et al., 2010). The BIN1-mediated 
recruitment and anchoring of Ca2+ channels to the tubule membrane might also take place in 
skeletal muscle. This idea is supported by the observation that BIN1 is at the sarcolemma and 
proximate tubule structures, which is the site of CaV1.1 accumulation during early tubule 
biogenesis. Dysferlin, on the other hand, localizes to tubule membranes in C2C12 myotubes 
which are more in the center of the cell. In adult myofibers, dysferlin also localizes to the T-
tubule system (Kerr et al., 2013).  Upon plasma membrane rupture, dysferlin-containing 
vesicles quickly accumulate at lesion sites and fuse with each other and with the plasma 
membrane to repair the membrane lesion (Lek et al., 2013; Redpath et al., 2014). Due to the 
incorporation of dysferlin in both, T-tubule membrane and repair vesicle membrane, it is 
suggestive that the T-tubule system represents the membrane reservoir that is provided to 
seal membrane ruptures. In this scenario, dysferlin-containing vesicles might be very quickly 
pinched off from the preexisting membrane tubule by an endocytosis-like mechanism and 
translocate to the site of membrane lesion. The possibility that the membrane reservoir, 
needed for lesion repair, origins from the plasma membrane is less conceivable as this process 
would require more steps of membrane modulation. Initially, membrane buds would have to 
be formed prior to pinching of and translocating to the lesion site, making this mechanism 
unfeasible for fast sarcolemma repair. Thus, the membranes needed for membrane lesion 
repair might arise from the T-tubules with dysferlin orchestrating the process of membrane 
modulation. The differentiation of myofibers is a very dynamic process with numerous 
membrane rearrangement events. The localization of dysferlin at central tubules inside the 
myofiber indicates that the protein has a role in dynamic membrane remodeling during 
membrane repair, but also development and maturation of the T-tubule system. The 
differential localization of endogenous dysferlin and BIN1 during T-tubule biogenesis and 
possible specific functions that are associated with their cellular localization might explain the 






5.2 Early developmental abnormalities of the T-tubule system in patient 
myoblasts due to dysferlin loss 
Dysferlinopathy is characterized by progressive weakening and wasting of the skeletal muscle. 
Histologically, muscles show typical signs of dystrophy including loss of muscle fibers, 
increased fiber size variation, and accumulation of connective and fat tissue. These 
phenotypes are secondary to defects in cellular functions and need to be investigated to 
understand the pathophysiology of dysferlin-deficient muscular dystrophy. The identification 
of primary molecular and cellular alterations is not simple, because many patients remain 
undiagnosed or maldiagnosed for several years after onset of symptoms (Harris et al., 2016). 
At the time point of correct diagnosis, muscular dystrophy is fairly advanced.  Thus, primary 
alterations of the skeletal muscle cannot easily be determined. Animal models of muscular 
dystrophy are therefore required in order to investigate the pathophysiology of dysferlin-
deficiency. The adult skeletal muscle T-tubule system of dysferlin-deficient mice shows 
dramatic rearrangements with dilated, irregularly shaped and longitudinally orientated 
tubules (Klinge et al., 2010a). Also during regeneration after notexin-induced muscle damage 
in a mouse model of dysferlin-deficiency, the T-tubule system is abnormally formed tubules 
are vacuolated (Hofhuis et al., 2017). As dysferlin plays a role during the biogenesis of the T-
tubule system (Hofhuis et al., 2017), the present study aimed to analyze the effect of dysferlin-
deficiency in a human model of early T-tubule development. The membrane system in a 
considerable proportion of patient myotubes is massively altered as assessed by membrane 
staining with the dye DiIC16(3). Instead of single tubules and vesicles as in control cells, dense 
bundles of longitudinal tubules in perinuclear regions were observed in dysferlin-deficient 
myotubes. This result shows that dysferlin is not only necessary for membrane repair and 
maintenance of T-tubules in adult myofibers, but the protein is essential during a very early 
stage of myofiber differentiation for proper biogenesis of the tubular network.  
 
Previous work of our group has identified a strong association between the phospholipid 
PI(4,5)P2 and dysferlin. Heterologous expression of dysferlin in non-muscle cells leads to 
formation of membrane tubules. PI(4,5)P2 is recruited to these dysferlin-containing tubules 
indicating that they share similarities with the T-tubule system of muscle cells, which are 
enriched in PI(4,5)P2 (Hofhuis et al., 2017; Milting et al., 1994). Additionally, the existence of 
PI(4,5)P2 and binding of dysferlin to PI(4,5)P2 is a prerequisite for dysferlin´s tubulation 
capacity. Thus, the function of dysferlin is highly dependent on PI(4,5)P2. As dysferlin is located 





PI(4,5)P2, dysferlin-deficiency might also lead to a reduced level of PI(4,5)P2 in membranes that 
usually contain dysferlin. PI(4,5)P2 is an important mediator of cellular signaling and trafficking 
(Hofgaard et al., 2008; Itoh and Takenawa, 2004; Suh and Hille, 2005; Sun et al., 2013; 
Takenawa et al., 1999). Among others, it anchors the growing plus-ends of microtubules at the 
plasma membrane (Golub and Caroni, 2005). It has been shown that dysferlin interacts with α-
tubulin and dysferlin-induced tubules depend on the microtubule system (Azakir et al., 2010; 
Hofhuis et al., 2017). Thus, the accumulation of membrane tubules in perinuclear bundles 
upon loss of dysferlin might be explained by the disability of the plasma membrane to anchor 
the microtubule-associated developing T-tubule system, which is deficient in dysferlin and 
probably therefore contains lower amount of PI(4,5)P2. 
 
5.3 Dysferlin is also a key player of cardiac tubule system biogenesis 
The implication of dysferlin in the development of the T-tubule system in skeletal muscle is 
based on the following findings: Dysferlin localizes to the developing and regenerating T-
tubule system in skeletal muscle (Hofhuis et al., 2017; Klinge et al., 2010a). Furthermore, the 
T-tubule system has an abnormal morphology upon dysferlin-deficiency (Klinge et al., 2010a). 
The results of this study show that the formation of the membrane system is disturbed in in 
patient myotubes. These observations correspond to the dystrophic symptoms affecting 
almost exclusively the skeletal muscles of dysferlinopathy patients. In only a few patients a 
cardiac dysfunction is reported (Kuru et al., 2004; Wenzel et al., 2006, 2007). By contrast, 
cardiac involvement is more pronounced in some mouse models of dysferlin-deficiency. 
Without excessive strain, no or only a mild cardiac phenotype is detected, whereas physical 
stress results in several signs of cardiac  dysfunction (Chase et al., 2009; Han et al., 2007; Rubi 
et al., 2015; Tzeng et al., 2014; Wei et al., 2015; Wenzel et al., 2007). Consequently, a putative 
role of dysferlin in the development of the cardiac tubule system was hypothesized and 
addressed in this study. In this study, expression and localization of dysferlin was analyzed in 
rat cardiomyocytes in the first three weeks of live, the time window when maturation of the 
cardiac tubule system occurs (Chen et al., 2013). Localization of dysferlin at the developing T-
tubule system was assessed by co-staining with the T-tubule marker CaV1.2 and appeared to 
increase over the course of 20 days after birth. Thus, before maturation of the transverse and 
axial membrane tubules dysferlin and CaV1.2 localize to different areas of the cardiomyocyte 
and co-assemble at membrane tubules during maturation. Cardiac dysferlin protein expression 
is similar in neonatal rats of P11 and adult rats. In the first three weeks of live, dysferlin 





tubular system is largely mature and transverse and axial tubules are achieving their final 
structure. Consequently, the expression pattern of dysferlin indicates that the protein is not 
only involved in the development of skeletal muscle T-tubule system, but also in the 
maturation of the cardiac TATS.  
 
The highly rearranged TATS in the cardiomyocytes of dysferlin-deficient mice strongly supports 
the hypothesis that dysferlin also exerts an important function in the heart: The distribution 
between transverse and axial orientated tubules is shifted to a higher amount of membrane 
components with axial orientation in dysferlin-deficient cardiomyocytes indicative of a 
reorientation of the TATS system. Not only transverse tubules get lost upon dysferlin-
deficiency, but also the total amount of membrane structures per cell is decreased, reducing 
the overall tubule length in mice lacking dysferlin. Thus, a disorganized T-tubule system upon 
deficiency of dysferlin is detected in both, skeletal and heart muscle substantiating the role of 
dysferlin in the biogenesis of the tubule system in both muscle types.  
 
Reorganization of the cardiac T-tubule system is a characteristic of patients suffering from 
heart failure and is verified in several animal models of heart failure (Gómez et al., 1997; 
Heinzel et al., 2008; Louch et al., 2004; Pieske et al., 1999). The rearrangements start very 
early in cardiac pathology even before the transition to heart failure, a condition when the 
metabolic demands of the body are insufficiently covered (Chen et al., 2015; Levy et al., 1996; 
Wei et al., 2010). The TATS of failing cardiomyocytes shows similar features as detected upon 
dysferlin-deficiency: loss of tubule system components, axialization and dilatation of 
membrane tubules (Cannell et al., 2006; Pinali et al., 2017; Wei et al., 2010). Thus, dysferlin-
deficiency might lead to a phenotype which is comparable to the early subclinical stages of 
heart failure without affection of heart function under normal conditions. Thereby, the 
abnormalities of the T-tubule system and resulting molecular changes can be compensated by 
the cells to prevent effects on a global level. Though, dysferlin-deficient mice have a disturbed 
cardiac function under physical stress. This indicates that the effects of a destructed cardiac 
TATS cannot be compensated if the requirements for the heart dramatically increase leading 
to detectable cardiac dysfunction.  
The distinct affection of skeletal and heart muscle upon dysferlin-deficiency might be 
explained by the structural and molecular differences between these two muscle types. 
Concretely, the diameter of skeletal muscle T-tubules is 5- to 10-fold smaller than the 





Wagner et al., 2012b). The membrane of cardiac tubules is extensively folded into 
microdomains with low ion diffusion (Hong et al., 2014). Such membrane folding has not been 
reported for the T-tubule system of skeletal myofibers. Transverse tubules occur in doublets 
with one tubule between each sarcomeric A- and I-band in skeletal myofibers, whereas only 
one tubule per sarcomere, which is anchored at the Z-line, is found in cardiomyocytes. 
Furthermore, cardiomyocytes have an intracellular membrane system composed of transverse 
and axial tubules forming a complex network (Forbes et al., 1984; Soeller and Cannell, 1999; 
Sperelakis and Rubio, 1971). Axial membrane tubules are largely missing in skeletal myofibers. 
In skeletal muscle cells, EC coupling occurs in triads with CaV1.1 and RyR1 physically interacting 
with each other presupposing that the T-tubule and SR membrane are separated by an 
extremely narrow gap (Ashcroft, 1991; Bezanilla et al., 1972; Boncompagni et al., 2006). In 
cardiomyocytes, CaV1.2 and RyR2 are only functionally coupled as Ca
2+ release from the SR is 
induced by Ca2+ influx through CaV1.2 and not by a conformational change of the channel 
(DiFranco et al., 2005; Fabiato, 1983; Hong and Shaw, 2017; Ibrahim et al., 2011). 
Consequently, cardiomyocytes might be more resistant to morphological changes of the 
tubule system than skeletal muscle cells as they do not depend on a direct association of the 
CaV1.2 with RyR2. This might explain that dysferlin-deficiency causing an abnormal tubule 
system in both, cardiomyocytes and skeletal myofibers, is mainly leading to clinical pathology 
of the skeletal and to a much lesser extent of the heart muscle.  
 
5.4 First stop on the route of dysferlin: the Endoplasmic reticulum 
To understand the pathomechanism underlying dysferlin-deficient muscular dystrophy and to 
develop therapeutic targets for this disease, the trafficking route of dysferlin through the 
myofiber or cardiomyocyte should be elucidated. Until now, very little is known about the 
transport of dysferlin from its synthesis in the cytoplasm to its target organelle, the plasma 
and T-tubule membrane. The nature of dysferlin as a TA protein with a highly hydrophobic 
transmembrane domain suggests that the protein is posttranslationally and chaperone-
assisted inserted into the membrane of the ER. This hypothesis was tested using a short 
peptide, the opsin tag, which is derived from the bovine rhodopsin (Adamus et al., 1991), as a 
sensor for ER integration. N-glycosylation of a specific arginine inside the recognition site of 
the opsin tag, which occurs through the activity of glycosyltransferases inside the ER lumen, 
can be detected by western blot as a mobility shift. As dysferlin has a molecular weight of 230 
kDa, a shift due to glycosylation of a single residue inside the opsin tag would not be visible. 





terminal fragment that is small enough to assess glycosylation on western blot either by anti-
dysferlin or anti-opsin antibodies. The coupling of dysferlin to the opsin tag and cleavage by 
thrombin was subsequently used to analyze insertion of dysferlin into the ER of different 
mammalian cell lines (HeLa, HEK293, COS-7, CHO-K1, C2C12). Indeed, dysferlin gets C-
terminally integrated into the ER in all tested systems suggesting that the ER membrane is the 
first endomembrane into which dysferlin is inserted after its synthesis in the cytoplasm. 
Surprisingly, the glycosylation is highly variable between the cell lines with CHO-K1 having the 
highest and HeLa the lowest amount of modified dysferlin. As glycosylation of dysferlin was 
also observed in C2C12 cells - a model system for myogenic development – it is possible that 
the posttranslational integration of dysferlin into the ER in muscle tissue is physiologically 
important. The variable glycosylation efficiency of dysferlin in different cell lines might be 
explained by several cellular factors. These include different chaperone proteins or complexes 
that might be involved in the cotranslational shielding or folding, protein quality control and 
targeting to the ER membrane (Casson et al., 2016; Hegde and Keenan, 2011; Johnson et al., 
2013). The components of the cytoplasmic and ER-membrane resident insertion machinery as 
well the glycosyltransferases inside the ER might be cell-type adapted (Aebi, 2013; Ellgaard et 
al., 2016; Johnson et al., 2013). Furthermore, glycosylation extent might be influenced by the 
duration of ER lumen exposure as some cell types might be more sensitive to ER stress then 
others resulting in the retention of proteins inside the ER (Oslowski and Urano, 2011; Sano and 
Reed, 2013). As dysferlin-ops was heterologously overexpressed in the tested cell lines, a 
certain degree of induced ER stress is plausible. Also, the morphology and the size of the ER is 
cell type-dependent and might influence the insertion of proteins into the ER.  
 
Patients with the DYSF mutation c.4022T>C show clinical symptoms of LGMD2B and partially 
of cardiomyopathy (Klinge et al., 2010b; Wenzel et al., 2006, 2007). Mutation c.4022T>C in 
exon 38 is leading to the amino acid change L1341P. The position L1341 is located in the C2E 
domain and is highly conserved, thus, an amino acid substitution might have dramatic effects 
on protein structure. Dysferlin L1341P accumulates in the ER of human myofibers and is prone 
to degradation by the autophagy-lysosome pathway (Fujita et al., 2007). In this study, the ER 
integration of wild-type and mutant dysferlin was analyzed to uncover possible trafficking 
defects of the mutant dysferlin. As expected, the proportion of glycosylated L1341P is 1.5-fold 
higher than glycosylated wild-type dysferlin. The increased amount of glycosylated protein 
might have different causes. Either, the integration into the ER is more efficient for the mutant 





prolonged leading to more opportunities for glycosyltransferases to glycosylate the opsin tag. 
Taking into consideration that the mutant L1341P does not localize to the plasma membrane 
in myofibers but rather accumulates in the ER (Fujita et al., 2007), the second explanation of 
increased glycosylation is more plausible. Substitution of leucine to proline at position 1341 
probably leads to a conformational change of the dysferlin protein which does not perturb 
insertion into the ER membrane. Instead, the altered protein structure interferes with 
dysferlin trafficking possible by inhibiting protein exit from the ER. This leads to loss of 
dysferlin at the plasma membrane and aggregation of L1341P inside the ER as detected in 
patient myofibers harboring the respective mutation (Fujita et al., 2007). Consequently, 
mutations inside conserved regions of dysferlin perturb cellular protein trafficking leading to 
deficiency of the full-length protein at its target organelle and causing muscular dystrophy.  
 
Dysferlin gets integrated into the membrane of the ER, but mechanistic details of this insertion 
are currently unknown. In recent years, a pathway has been identified, that mediates insertion 
of TA proteins into the ER and which is also involved in protein quality control (Favaloro et al., 
2010; Payapilly and High, 2014; Rodrigo-Brenni et al., 2014; Stefanovic and Hegde, 2007; 
Vilardi et al., 2011; Yamamoto and Sakisaka, 2012). The dependence of the TA protein 
dysferlin on the TRC40/WRB insertion pathway in cardiomyocytes was analyzed in cooperation 
with Dr. Jhon Rivera-Monroy and Prof. Blanche Schwappach from the department of 
Molecular Biology, University Medical Center Göttingen. The ER membrane-located receptor 
component WRB was cardiac-specifically deleted in an inducible mouse model. This leads not 
only to a significant reduction of WRB protein level, but also the steady-state levels of other 
main pathway components, TRC40 and CAML, decrease upon WRB gene deletion resulting to 
complete disruption of the pathway (Rivera-Monroy et al., 2016). Cardiomyocytes were 
isolated from 8-week old mice and 2 weeks after gene knockout induction by administration of 
tamoxifen (Performed by Dr. Jhon Rivera-Monroy). Cells were analyzed with regard to 
dysferlin expression and localization by western blot and indirect immunofluorescence, 
respectively. Neither the steady-state protein level, nor the localization of dysferlin is affected 
by disruption of the TRC40/WRB pathway in ventricular cardiomyocytes. These results indicate 
a probable TRC40/WRB-independent trafficking of dysferlin in cardiomyocytes, although the 
missing effect on dysferlin upon TRC40/WRB disruption does not exclude that dysferlin might 
be targeted via this pathway to the ER. Alternative chaperone and insertion pathways have 
been identified previously, which operate in parallel and to some extent might compensate for 





2008). TA proteins containing a transmembrane domain with comparably high hydrophobicity, 
like in the case of dysferlin, are suitable candidates for ER insertion via the TRC40/WRB 
pathway (Rabu et al., 2008). As TRC40/WRB disruption does not lead to a mislocalized or 
destabilized dysferlin pool, the hydrophobicity is not the only criterion which dictates whether 
a certain TA is an obligatory client for the TRC40/WRB pathway (Rivera-Monroy et al., 2016). 
Dysferlin has a very large N-terminal domain upstream of the transmembrane domain 
incorporating seven C2 domains and several other domains which require proper folding and 
quality control already during the process of translation. This might be ensured by specialized 
cytosolic chaperones. BAG6, which is also a component of the cytosolic TRC40 chaperone 
complex, is additionally involved in quality control. Mislocalized proteins are BAG6-
dependently polyubiquitinated by the ubiquitin ligase RNF126 and subsequently degraded by 
the proteasome (Rodrigo-Brenni et al., 2014). It has been reported that the proteasome is 
involved in the degradation of wild-type dysferlin (Fujita et al., 2007). Thus, it is conceivable 
that the BAG6-mediated initiation of proteasomal degradation is one component of the 
quality control system necessary for proper dysferlin synthesis. In conclusion, dysferlin is C-
terminally inserted into the membrane of the ER probably directly after its synthesis and this 
process does not depend on the TRC40/WRB integration pathway.  
 
5.5 4-Phenylbutyrate as potential therapeutic for the treatment of 
dysferlinopathy 
Dysferlin-deficiency is often associated with dysferlin mislocalization, instability and/or 
degradation due to mutations in the DYSF gene. In this study two missense mutants were 
analyzed with regard to possible therapeutic intervention. Mutation R959W is located in the 
C2D domain and is reported to cause structural changes in the dysferlin protein (Espinoza-
Fonseca, 2016). Dysferlin harboring the mutation L1341P, which is located in the C2E domain, 
is prone to aggregation in the ER (Fujita et al., 2007). In this study, the steady-state protein 
level is decreased for both dysferlin variants compared to wild-type dysferlin. Treatment with 
PBA leads to an increased levels of wild-type, R959W and L1341P proteins with mutant R959W 
exceeding the basal wild-type level. Thus, PBA is a potent substance for the amelioration of 
reduced mutant dysferlin protein level in dysferlinopathy. There are several possible 
mechanisms by which PBA elevates the protein level of dysferlin variants. One is the general 
function of PBA as a chaperone (Cortez and Sim, 2014). The hydrophobic chain of PBA might 





folding and probably reducing the unfolded protein response which would lead to protein 
degradation (Lindholm et al., 2017). This could explain the effect that not only mutant 
dysferlin variants, but also the wild-type dysferlin becomes stabilized. Dysferlin is a large 
protein making it plausible that folding errors occur also under normal conditions. Thus, PBA 
may assist in protein folding and thereby increase steady-state levels of dysferlin wild-type 
and mutants. Recently, the mode of action of PBA as a regulator of proteostasis was addressed 
by Ma and colleagues (Ma et al., 2017). They hypothesize that PBA affects trafficking from the 
ER to the Golgi via COPII-coated vesicles. Accordingly, PBA displaces the protein p24 from 
binding to COPII proteins and thereby reduces stringency of misfolded protein retention inside 
the ER (Ma et al., 2017). By this mechanism, dysferlin variants, which are partially ER-trapped 
under basal conditions, would be extruded from the ER by PBA. A distinct line of research has 
uncovered a role of PBA in inducing the expression of the 70-kDa heat shock protein (Hsp70), 
which is activated upon ER stress and binds to unfolded or misfolded proteins (Choo-Kang and 
Zeitlin, 2001). It was suggested that PBA induces Hsp70 expression via activation of elongator 
protein 2 (ELP2) and signal transducer and activator of transcription-3 (STAT-3). Hsp70 in turn 
mediates maturation and trafficking of mutated forms of cystic fibrosis transmembrane 
conductance regulator (CFTR), the cause for cystic fibrosis (Choo-Kang and Zeitlin, 2001; Suaud 
et al., 2011). Thus, stabilization of dysferlin R959W and L1341P steady-state protein level 
might also be mediated by induction of Hsp70 alleviating the degradation of these mutants. 
Additionally to a chaperone-mediated elevation of dysferlin protein, the function of PBA as 
histone deacetylase inhibitor might ameliorate reduced protein level by modulating cellular 
gene expression.  
 
Several lines of evidence suggest that the deformation of membranes into elongated tubules 
during biogenesis of the T-tubule system is the primary function of dysferlin in the muscle 
fiber (Hofhuis et al., 2017). The induction of membrane tubules upon heterologous expression 
of dysferlin in non-muscle cells is considered as analogous to its physiological function. Thus, 
the ability to tubulate membranes in non-muscle cells can be used as a read-out for proper 
dysferlin function (Hofhuis et al., 2017). The dysferlin mutants R959W and L1341P were 
analyzed with regard to their functionality using this assay. Both mutants are incapable in the 
generation of membrane tubules when expressed in HeLa cells. R959W is partially colocalizing 
with the cis-Golgi marker giantin (Linstedt and Hauri, 1993; Puthenveedu and Linstedt, 2001). 
As the overlap was not complete, it is conceivable that this mutant rather is trapped in the 





reported, L1341P is found to be retained in the ER (Fujita et al., 2007). Taking into 
consideration that both mutants harbor only a single amino acid substitution, which obviously 
affects protein trafficking, it is plausible that they might be functional when localized at the 
appropriate cellular position. As steady-state protein level is stabilized by PBA, also the effect 
on mutant localization was analyzed. Wild-type and L1341P localization is unaffected by PBA 
treatment. Mutant R595W is mainly localizing to the Golgi compartment, but also the 
induction of membrane tubules is detectable in a considerable proportion of cells. 
Consequently, the elevation of R959W steady-state level by PBA-mediated improvement of 
trafficking leads to some extent to correct localization of mutant dysferlin and partial 
restoration of its function as membrane modulator. In contrast to R959W, the mutant L1341P 
does not lead to detectable generation of membrane tubules even upon PBA treatment. This 
might be explained by the different steady-state levels that are reached by PBA. The level of 
R959W exceeds the basal level of wild-type dysferlin. These results indicate that even higher 
amounts of mutant R959W upon PBA compared to nontreated wild-type dysferlin, only 
partially restore the function of R959W because of structural changes due to the amino acid 
change. Steady-state levels of L1341P upon PBA treatment are still lower than levels of 
untreated wild-type dysferlin. Thus, either the improved trafficking for the mutant is not 
sufficient to restore tubulation in the cell system, or the mutation leads not only to retention 
inside the ER but also to loss of function. Assuming that dysferlin follows the secretory 
pathway to traffic from the ER through the Golgi to its target membrane (Azakir et al., 2010), 
the mutant L1341 gets trapped at an earlier stage of this route than the mutant R959W 
making it putatively easier for the latter to be extruded by pharmacological intervention. 
Further investigation is necessary to assess whether PBA might have an ameliorating effect on 
the functionality of L1341P mutated dysferlin under different conditions or other systems. In 
conclusion, PBA is a potent pharmacological substance for the restoration of dysferlin 
function, as shown for the mutant R959W. To determine, whether the functional rescue 
observed in a cell culture system can be confirmed in vivo, the efficiency of PBA treatment in 
dysferlin-deficient animal models harboring point mutations needs to be investigated regard 
to progression of muscular dystrophy. PBA is considered as a safe and well-tolerable 
compound with only mild and reversible adverse effects (Mokhtarani et al., 2013; Perrine et 
al., 2011). Though, effects on the amino acid homeostasis, caused by the metabolism of PBA, 
with decreased blood plasma levels of glutamine and branch-chained amino acids valine, 
leucine, isoleucine, have been reported (Brunetti-Pierri et al., 2011; Burrage et al., 2014; 





branch-chained amino acids was recently recommended for the clinical use of PBA (Holecek et 
al., 2017). PBA is under investigation for the treatment of several diseases and might also be a 
potent pharmacological therapeutic for dysferlinopathy. As PBA is already FDA-approved for 
the treatment of children with urea cycle disorders, it might be feasible to perform clinical 
trials investigating PBA as treatment for dysferlinopathy in the near future.   
 
5.6 Therapeutic modulation of dysferlin expression by translational 
readthrough  
25% of recurrent mutations in the DYSF gene that cause dysferlin-deficiency and the 
development of muscular dystrophy are mutations leading to the generation of termination 
codons (UMD-DYSF mutations database, http://www.umd.be/DYSF/W_DYSF/mutation.html). 
These stop signals cause mRNA instability and nonsense-mediated mRNA decay, or the 
premature termination of translation resulting in the production of truncated unfunctional 
proteins that are prone to degradation (Yang et al., 2016). Aminoglycosides can provoke the 
binding of a near-cognate aminoacyl-tRNA instead of a release factor at premature 
termination codons (PTCs) by interacting with conserved ribosomal RNA in the ribosomal 
decoding center (Wimberly et al., 2000). This leads to the incorporation of an amino acid, 
continuation of translation and synthesis of the full-length protein (Lee and Dougherty, 2012). 
This approach is approved for the treatment of cystic fibrosis patients and is under 
investigation for other genetic diseases with premature stop codons, such as Duchenne 
muscular dystrophy (Barton-Davis et al., 1999; Lee and Dougherty, 2012; Loufrani et al., 2004). 
The in vivo use of aminoglycosides gentamicin and G418 as readthrough inducers is 
accompanied by severe adverse effects of those drugs. Oto- and nephrotoxicity are the most 
critical side effects reported (Smyth, 2010). Therefore, a prediction for the treatability of 
certain PTCs by aminoglycosides would be beneficial for the patients to avoid ineffective 
readthrough induction and severe side effects. This concept was addressed by the treatment 
of cystic fibrosis and Duchenne muscular dystrophy (Bidou et al., 2004; Howard et al., 2000; 
Sermet-Gaudelus et al., 2007). In a systematic analysis, the basal and G418-induced 
readthrough of the 18 recurrent nonsense codons known in dysferlinopathy patients was 
assessed in this study. For this purpose, a very sensitive dual reporter expressing TagRFP and 
EGFP fluorescent protein genes upstream and downstream of an SCC, respectively, was used. 
Interestingly, a variable level of basal and G418-induced readthrough was detected indicating 





work of our group showed that only the stop codon itself and the adjacent nucleotides have a 
dominant impact on the basal readthrough propensity (Schueren et al., 2014). The estimation 
of readthrough propensity for all SCCs of the human genome by an in silico regression model 
lead to the identification of a 6-nucleotide consensus motif for high readthrough tendency: 
UGA CUA (stop codon in bold, positions 1-6, (Schueren et al., 2014). The stop codon UGA is 
reported to be most leaky with regard to readthrough (Howard et al., 2000; Schueren et al., 
2014; Tate et al., 1996). All of the five patient mutations with SCCs yielding the highest 
induced readthrough levels in our assay (R1038X, S1173X, Q1269X, C1398X, W1968X) harbor 
the UGA stop codon (table). The high-readthrough consensus motif (Schueren et al., 2014) 
indicates that a cytosine (C) at position +4 correlates with high basal readthrough, but also the 
readthrough level achieved by induction with aminoglycosides is positively influenced by this 
nucleotide at the respective position (Howard et al., 2000; Keeling and Bedwell, 2002; 
Manuvakhova et al., 2000). Based on their results using a dual reporter assay for the 
assessment of readthrough induction, Howard and colleagues have graded the four 
nucleotides at position +4 according to their positive influence on readthrough and showed 
that C is the most powerful nucleotide following by uracil (U). The five SCCs with the highest 
induced readthrough in our assay harbor either a C (R1038X, Q1269X, C1398X) or a U (S1173X, 
W1968X). Therefore, the results obtained for the SCCs of DYSF nonsense mutations are in 
concordance with previously reported data. Schueren et al. suggested that a guanine (G) at 
position +7 might also contribute to high basal readthrough (Schueren et al., 2014). 
Interestingly, all of the five SCCs with highest G418-induced readthrough have a C at position 
+7. Thus, a G at this position may correlate with high readthrough under basal conditions, but 
when aminoglycosides are bound to the ribosome a C at position +7 of the mRNA may be 
more beneficial for readthrough induction. Howard and colleagues proposed an inverse 
correlation between the induced readthrough level and the stringency of translational 
termination in the absence of aminoglycosides (Howard et al., 2000). This observation was not 
reflected by this study as no correlation was observed between basal and induced 
readthrough levels. The results of this study indicate that basal readthrough of a given SCC is 
positively influenced by a distinct nucleotide composition then readthrough upon induction 
with aminoglycosides. This hypothesis is supported by the observation that a G at position +7 
correlates with high basal readthrough (Schueren et al., 2014), but a C at the same position is 
located in all of the five SCCs with highest induced readthrough in this study. The results 
obtained by analysis of DYSF nonsense SCCs indicate that the benefit of aminoglycoside 





whether knowledge of readthrough levels derived from a cell culture system can be translated 
to the therapeutic success in clinics. The comparison of readthrough induction in a dual 
reporter assay and the animal model of Duchenne muscular dystrophy by Bidou and 
colleagues led to the conclusion that results obtained in a cell culture system cannot be 
transferred into in vivo systems (Bidou et al., 2004). The work of Sermet-Gaudelus and 
colleagues contradicted this conclusion (Sermet-Gaudelus et al., 2007). They analyzed 
readthrough induction of SCCs from all nonsense mutations found in cystic fibrosis patients by 
a dual reporter assay and compared these results to the beneficial effects of aminoglycoside 
treatment of cystic fibrosis patients. The readthrough levels obtained in the reporter assay 
correlate with the production of the full-length protein in nasal epithelial cells of the treated 
patients suggesting that a dual reporter assay used in a cell culture system has the potency to 
predict therapeutic success (Sermet-Gaudelus et al., 2007). Another study analyzed the 
production of full-length protein in patients treated with aminoglycosides and their initial level 
of the targeted transcript. Accordingly, patients with high levels of transcript prior to 
treatment showed better response to readthrough therapy. This indicates that the process of 
nonsense-mediated mRNA decay and therewith the level of transcript should be considered 
for each patient (Linde et al., 2007). In conclusion, the sensitive dual reporter assay used in 
this study to assess basal and G418-induced readthrough of patient SCCs may be suitable as a 
prediction for the treatability of dysferlinopathy patients with nonsense mutations. According 
to the obtained results upon G418 treatment, patients harboring the mutations R1038X, 
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